1
00:00:05,200 --> 00:00:06,000
>>WELCOME TO THE OPEN

2
00:00:06,000 --> 00:00:08,000
SESSION OF THE 202nd MEETING

3
00:00:08,000 --> 00:00:10,280
OF THE ALLERGY AND INSPECTION

4
00:00:10,280 --> 00:00:12,760
ANXIOUS DISEASE.

5
00:00:12,760 --> 00:00:14,160
AS YOU KNOW, DURING THE OPEN

6
00:00:14,160 --> 00:00:15,440
SESSIONS WE'RE JOINED FROM

7
00:00:15,440 --> 00:00:16,400
PROFESSIONAL AND LAY

8
00:00:16,400 --> 00:00:17,000
ORGANIZATION WHO'S SHARE

9
00:00:17,000 --> 00:00:19,920
INTEREST AND ACTIVITIES IN

10
00:00:19,920 --> 00:00:21,240
COMMON WITH THE MISSION OF THE

11
00:00:21,240 --> 00:00:21,680
INSTITUTE.

12
00:00:21,680 --> 00:00:23,560
WE WELCOME THEM, AS ALWAYS, AND

13
00:00:23,560 --> 00:00:27,400
I'D LIKE TO ALSO WELCOME TWO AD

14
00:00:27,400 --> 00:00:30,440
HOC DAIT COUNCIL MEMBERS WHO ARE

15
00:00:30,440 --> 00:00:31,600
JOINING US TODAY.

16
00:00:31,600 --> 00:00:33,320
Dr. DAVID ARTIST IS THE

17
00:00:33,320 --> 00:00:35,600
MICHAEL KORS PROFESS OF

18
00:00:35,600 --> 00:00:37,840
IMMUNOLOGY IN THE DEPARTMENT OF

19
00:00:37,840 --> 00:00:41,000
MEDICINE WITH THE CORNELL

20
00:00:41,000 --> 00:00:43,600
MEDICAL COLLEGE AND Dr. DEB

21
00:00:43,600 --> 00:00:51,120
ROSS KEY HERMIGHT FR IMMUNEEL GE

22
00:00:51,120 --> 00:00:52,560
AND PATHO BIOLOGY.

23
00:00:52,560 --> 00:00:54,080
WE ARE DELIGHTED TO HAVE THESE

24
00:00:54,080 --> 00:00:57,160
TWO AD HOC MEMBERS WITH US

25
00:00:57,160 --> 00:00:57,520
TODAY.

26
00:00:57,520 --> 00:01:02,880
COUNCIL MEMBERS Dr. LINDA

27
00:01:02,880 --> 00:01:04,040
BAKKENSTED IS UNABLE TO BE WITH

28
00:01:04,040 --> 00:01:04,840
US TODAY.

29
00:01:04,840 --> 00:01:07,120
WITH REGARD TO THE MINUTES, THE

30
00:01:07,120 --> 00:01:08,680
FIRST ITEM OF BUSINESS IS TO

31
00:01:08,680 --> 00:01:09,560
REVIEW AND APPROVE THE MINUTES

32
00:01:09,560 --> 00:01:11,000
FROM THE LAST MEETING.

33
00:01:11,000 --> 00:01:12,560
YOU SHOULD ALREADY HAVE SEEN A

34
00:01:12,560 --> 00:01:14,320
COPY OF THE MINUTES IN THE

35
00:01:14,320 --> 00:01:16,680
ELECTRONIC COUNCIL BOOK.

36
00:01:16,680 --> 00:01:18,800
ARE THERE ANY CORRECTIONS TO THE

37
00:01:18,800 --> 00:01:19,400
MINUTES?

38
00:01:19,400 --> 00:01:20,960
DOES ANYONE HAVE ANY QUESTIONS

39
00:01:20,960 --> 00:01:23,040
OR CONCERNS ABOUT THE CONCEPTS

40
00:01:23,040 --> 00:01:26,680
PRESENTED AT THE PREVIOUS

41
00:01:26,680 --> 00:01:27,520
MEETING?

42
00:01:27,520 --> 00:01:30,520
IF NOT, MAY I HAVE A MOTION FOR

43
00:01:30,520 --> 00:01:30,920
APPROVAL?

44
00:01:30,920 --> 00:01:32,880
IS THERE A SECOND?

45
00:01:32,880 --> 00:01:34,320
ALL IN FAVOR OF THE MINUTES,

46
00:01:34,320 --> 00:01:38,240
PLEASE A AYE.

47
00:01:38,240 --> 00:01:40,840
ANY OPPOSED?

48
00:01:40,840 --> 00:01:42,960
THE MINUTES STAND AS APPROVED.

49
00:01:42,960 --> 00:01:46,560
NOW, LET'S GET ON WITH THE

50
00:01:46,560 --> 00:01:50,000
FORMAL REMARKS TO THE COUNCIL.

51
00:01:50,000 --> 00:01:52,360
PRESIDENT JOE BIDEN HAS

52
00:01:52,360 --> 00:01:56,400
NOMINATED Dr. ARATI PRABHAKAR

53
00:01:56,400 --> 00:01:59,120
TO SERVE AS THE DIRECTING OFF

54
00:01:59,120 --> 00:02:01,680
THE OF THE WHITE HOUSE OFFICE OF

55
00:02:01,680 --> 00:02:03,960
SCIENCE OF THE OSTP.

56
00:02:03,960 --> 00:02:06,680
ONCE CONFIRMED TO THIS POSITION,

57
00:02:06,680 --> 00:02:08,440
SHE ALSO WOULD SERVE AS

58
00:02:08,440 --> 00:02:09,520
ASSISTANT TO THE PRESIDENT FOR

59
00:02:09,520 --> 00:02:12,240
SCIENCE AND TECHNOLOGY AS IS

60
00:02:12,240 --> 00:02:15,480
CHIEF ADVISER THE SCIENCE AND

61
00:02:15,480 --> 00:02:18,040
TECHNOLOGY, SHE WOULD BE A

62
00:02:18,040 --> 00:02:18,800
CABINET MEMBER.

63
00:02:18,800 --> 00:02:20,400
THE SENATE CONFIRMATION PROCESS

64
00:02:20,400 --> 00:02:26,600
FOR HER NOMINATION, IS CURRENTLY

65
00:02:26,600 --> 00:02:27,280
UNDERWAY.

66
00:02:27,280 --> 00:02:30,040
SHE, A HIGHLY RESPECTED ENGINEER

67
00:02:30,040 --> 00:02:32,440
AND APPLIED PHYSICIST, SERVED IN

68
00:02:32,440 --> 00:02:36,680
PREVIOUS ADMINISTRATIONS AS

69
00:02:36,680 --> 00:02:38,040
DIRECTOR OF TAP ADDRESS AND

70
00:02:38,040 --> 00:02:39,680
TECHNOLOGY AND THE DEFENSE

71
00:02:39,680 --> 00:02:47,360
ADVANCED RESEARCH PROJECT AGENCY

72
00:02:47,360 --> 00:02:48,800
OR.

73
00:02:48,800 --> 00:02:51,040
THE ADMINISTRATION ANNOUNCED THE

74
00:02:51,040 --> 00:02:52,200
APPOINTMENT OF THE SEASON

75
00:02:52,200 --> 00:02:56,200
EMERGENCY MANAGEMENT LEADER

76
00:02:56,200 --> 00:02:59,120
ROBERT FENTON UNION AS THE WHITE

77
00:02:59,120 --> 00:03:00,760
HOUSE NATIONAL MONKEYPOX

78
00:03:00,760 --> 00:03:03,440
COORDINATOR.

79
00:03:03,440 --> 00:03:07,960
Dr. DEMETRE DASKALAKIS, A

80
00:03:07,960 --> 00:03:10,480
HELPER THE CDC DIVISION OF HIV

81
00:03:10,480 --> 00:03:12,680
PREVENTION WAS NAMED THE DEPUTY

82
00:03:12,680 --> 00:03:13,400
COORDINATOR.

83
00:03:13,400 --> 00:03:15,800
THE STRATEGIC AND OPERATIONAL

84
00:03:15,800 --> 00:03:17,920
RESPONSE TO THE MONKEYPOX

85
00:03:17,920 --> 00:03:21,200
OUTBREAK IS NOW BEING LED BY

86
00:03:21,200 --> 00:03:22,400
THESE TWO INDIVIDUALS WITH

87
00:03:22,400 --> 00:03:25,760
DECADES OF RELEVANT AND

88
00:03:25,760 --> 00:03:27,000
COMPLIMENTARY EXPERIENCE, Mr.

89
00:03:27,000 --> 00:03:29,960
FENTON SERVED AS ACTING FEMUR

90
00:03:29,960 --> 00:03:31,560
ADMINISTRATOR AND LED MULTIPLE

91
00:03:31,560 --> 00:03:32,840
CHALLENGING OPERATIONS

92
00:03:32,840 --> 00:03:35,080
THROUGHOUT HIS CAREER.

93
00:03:35,080 --> 00:03:40,880
PRIOR TO JOINING THE CDC, Dr.

94
00:03:40,880 --> 00:03:42,920
DASKLAAKIS OVER AWE INFECTIOUS

95
00:03:42,920 --> 00:03:44,080
DISEASE MANAGEMENT FOR THE

96
00:03:44,080 --> 00:03:46,320
DEPARTMENT OF HEALTH AND MENTAL

97
00:03:46,320 --> 00:03:47,400
HYGIENE IN NEW YORK CITY.

98
00:03:47,400 --> 00:03:50,360
BOTH PLAYED CRITICAL ROLES IN

99
00:03:50,360 --> 00:03:56,360
MAKING COVID-19 VACCINES MORE

100
00:03:56,360 --> 00:03:57,360
ACCESSIBLE TO UNDERSERVED

101
00:03:57,360 --> 00:03:57,680
COMMUNITIES.

102
00:03:57,680 --> 00:04:01,880
IN JULY, FDA COMMISSIONER, Dr.

103
00:04:01,880 --> 00:04:03,400
ROBERT KAYLORA ANNOUNCED THE

104
00:04:03,400 --> 00:04:05,400
SELECTION OF TWO OUTSTANDING

105
00:04:05,400 --> 00:04:06,840
PROFESSIONALS TO FILL IMPORTANT

106
00:04:06,840 --> 00:04:09,200
SENIOR LEADERSHIP POSITIONS AT

107
00:04:09,200 --> 00:04:12,840
THE AGENCY.

108
00:04:12,840 --> 00:04:15,880
Dr. BUMPIS WHO SERVED AS

109
00:04:15,880 --> 00:04:17,680
DIRECTOR OF THE DEPARTMENT OF

110
00:04:17,680 --> 00:04:19,080
MOLECULAR SCIENCES AND

111
00:04:19,080 --> 00:04:20,280
PHARMACOLOGY AT THE JOHNS

112
00:04:20,280 --> 00:04:21,240
HOPKINS SCHOOL OF MEDICINE IS

113
00:04:21,240 --> 00:04:24,080
THE NEW FDA CHIEF SCIENTIST.

114
00:04:24,080 --> 00:04:28,120
Dr. HILARY MARSTON A

115
00:04:28,120 --> 00:04:29,600
HIGHLY-VALUED COLLEAGUE, WHO

116
00:04:29,600 --> 00:04:30,680
PREVIOUSLY SERVED IN MY OFFICE

117
00:04:30,680 --> 00:04:34,920
AS MEDICAL OFFICER AND POLICY

118
00:04:34,920 --> 00:04:35,960
ADVISER FOR GLOBAL HEALTH AND

119
00:04:35,960 --> 00:04:38,200
MOST RECENTLY AS THE WHITE HOUSE

120
00:04:38,200 --> 00:04:41,120
SENIOR POLICY ADVISER ON

121
00:04:41,120 --> 00:04:43,240
COVID-19, IS NOW THE CHIEF

122
00:04:43,240 --> 00:04:47,880
MEDICAL OFFICER AT FDA.

123
00:04:47,880 --> 00:04:48,880
PRESIDENT JOE BIDEN HAS SELECTED

124
00:04:48,880 --> 00:04:54,080
Dr. MONICA BERKTECHNOLI AS A

125
00:04:54,080 --> 00:04:55,520
CLINICIAN AND AN EXECUTIVE AS

126
00:04:55,520 --> 00:04:57,480
THE NEXT DIRECTOR IN THE FIRST

127
00:04:57,480 --> 00:04:58,880
WOMAN TO LEAD THE NATIONAL

128
00:04:58,880 --> 00:05:01,240
CANCER INSTITUTE.

129
00:05:01,240 --> 00:05:03,160
CURRENTLY, Dr. BERT AGO

130
00:05:03,160 --> 00:05:05,880
KNOWLEDGE' IS THE RICHARD E.

131
00:05:05,880 --> 00:05:08,160
WILLIAM PROFESSOR OF SURGERY AT

132
00:05:08,160 --> 00:05:09,600
HARVARD MEDICAL SCHOOL AND SHE

133
00:05:09,600 --> 00:05:14,840
HOLD POSITIONS AT BRIGHAM.

134
00:05:14,840 --> 00:05:16,040
SHE WILL TAKE OVER THE REIGNS

135
00:05:16,040 --> 00:05:18,040
FROM Dr. DOUG LOWY WHO HAS

136
00:05:18,040 --> 00:05:21,680
BEEN SERVING AS ACTING NIH/NCI

137
00:05:21,680 --> 00:05:24,200
DIRECTOR SINCE FORMER NCI

138
00:05:24,200 --> 00:05:27,680
DIRECTOR Dr. NED SHARPLESS

139
00:05:27,680 --> 00:05:28,600
STEPPED DOWN LAST SPRING.

140
00:05:28,600 --> 00:05:30,480
IN JUNE, ACTING NIH DIRECTOR

141
00:05:30,480 --> 00:05:32,240
Dr. LARRY TABAK ANNOUNCED THE

142
00:05:32,240 --> 00:05:34,240
SELECTION OF KEVIN WILLIAMS AS

143
00:05:34,240 --> 00:05:36,360
THE DIRECTOR OF THE NIH OFFICE

144
00:05:36,360 --> 00:05:38,640
OF EQUITY, DIVERSITY AND

145
00:05:38,640 --> 00:05:40,920
INCLUSION OR EDI.

146
00:05:40,920 --> 00:05:43,760
KEVIN JOINS NIH FROM THE U.S.

147
00:05:43,760 --> 00:05:44,600
FEDERAL TRADE COMMISSION WHERE

148
00:05:44,600 --> 00:05:47,920
HE MOST RECENTLY HELD A POSITION

149
00:05:47,920 --> 00:05:49,520
OF DEPUTY EXECUTIVE DIRECTOR.

150
00:05:49,520 --> 00:05:51,440
HE WILL GUIDE THE STRATEGIC

151
00:05:51,440 --> 00:05:55,920
DIRECTION FOR NIH ON ALL

152
00:05:55,920 --> 00:05:57,880
INCERTAINAL EDI MATTERS.

153
00:05:57,880 --> 00:06:02,080
LET ME DIGRESS TO BRING YOU

154
00:06:02,080 --> 00:06:05,840
UP-TO-DATE ON NIAID ACTIVITIES

155
00:06:05,840 --> 00:06:06,480
IN THIS AREA.

156
00:06:06,480 --> 00:06:08,240
MANY OF YOU MAY BE AWARE OF

157
00:06:08,240 --> 00:06:09,560
EFFORTS ACROSS THE NIH TO

158
00:06:09,560 --> 00:06:11,440
ENHANCE DIVERSITY, EQUITY,

159
00:06:11,440 --> 00:06:15,960
INCLUSION AND ACCESSIBILITY OR

160
00:06:15,960 --> 00:06:16,400
DEIA.

161
00:06:16,400 --> 00:06:21,400
IN CARRYING OUT OUR MISSION,

162
00:06:21,400 --> 00:06:22,640
NIAID IS COMMITTED TO FOSTERING

163
00:06:22,640 --> 00:06:26,040
A WORKPLACE THAT EMBODIES AND

164
00:06:26,040 --> 00:06:27,440
VALUES THE DIVERSE STAFF.

165
00:06:27,440 --> 00:06:29,480
THE FUNDS IN EXTRA RESEARCH

166
00:06:29,480 --> 00:06:30,520
PORTFOLIO INCLUSIVE OF THE

167
00:06:30,520 --> 00:06:33,560
VARIOUS POPULATIONS IT SERVICE

168
00:06:33,560 --> 00:06:35,160
AND THAT PRIORITIZES HEALTH

169
00:06:35,160 --> 00:06:38,320
EQUITY IN ALL RESEARCH THAT

170
00:06:38,320 --> 00:06:39,600
NIAID CONDUCTS AND SUPPORTS.

171
00:06:39,600 --> 00:06:43,960
AS PART OF THIS COMMITMENT,

172
00:06:43,960 --> 00:06:46,560
NIAID HAS ESTABLISHED AN

173
00:06:46,560 --> 00:06:49,720
INTERNAL DEIA COUNCIL ADVISING

174
00:06:49,720 --> 00:06:52,200
OUR LEADERSHIP ON MANY OF THESE

175
00:06:52,200 --> 00:06:56,440
ACTIVITIES GOING FORWARD.

176
00:06:56,440 --> 00:06:58,520
TO GATHER INFORMATION FROM AN

177
00:06:58,520 --> 00:07:00,880
EXTRAMURAL COMMUNITY TO ENHANCE

178
00:07:00,880 --> 00:07:03,600
DEIA ACROSS NIAID ACTIVITIES,

179
00:07:03,600 --> 00:07:06,720
WE'LL BE ISSUING A REQUEST FOR

180
00:07:06,720 --> 00:07:08,000
INFORMATION THIS FALL.

181
00:07:08,000 --> 00:07:11,520
THE RFI IS INTENDED TO INFORM US

182
00:07:11,520 --> 00:07:13,560
OF POTENTIAL APPROACHES TO

183
00:07:13,560 --> 00:07:17,040
ADVANCE DEIA AND TO ENSURE THAT

184
00:07:17,040 --> 00:07:21,080
ALL AVAILABLE PERSPECTIVES ARE

185
00:07:21,080 --> 00:07:22,640
CONSIDERED AS NIAID DEVELOPS AND

186
00:07:22,640 --> 00:07:25,120
IMPLEMENTS DEIA STRATEGIES.

187
00:07:25,120 --> 00:07:27,800
WE ENCOURAGE THE EXTRAMURAL

188
00:07:27,800 --> 00:07:29,840
RESEARCH COMMUNITY TO SHARE YOUR

189
00:07:29,840 --> 00:07:34,480
THOUGHTS WITH US IN THIS

190
00:07:34,480 --> 00:07:35,800
IMPORTANT DISCUSSION.

191
00:07:35,800 --> 00:07:38,400
NOW LET ME GET BACK TO A FEW

192
00:07:38,400 --> 00:07:39,960
MORE PERSONNEL UPDATES.

193
00:07:39,960 --> 00:07:42,320
THE DIVISION OF EXTRAMURAL

194
00:07:42,320 --> 00:07:44,560
ACTIVITIES SELECTED EILEEN LOUIS

195
00:07:44,560 --> 00:07:47,040
AS A NEW BRANCH CHIEF IN THE

196
00:07:47,040 --> 00:07:48,600
OFFICE OF ACQUISITIONS.

197
00:07:48,600 --> 00:07:50,760
SHE WILL OVERSEE RESEARCH

198
00:07:50,760 --> 00:07:55,320
CONTRACTS, BRANCH B. AND HER

199
00:07:55,320 --> 00:07:56,520
EXPERIENCE HAS CONTRACT

200
00:07:56,520 --> 00:07:59,320
MANAGEMENT ACQUISITION AND SPANS

201
00:07:59,320 --> 00:08:01,480
MORE THAN 28 YEARS.

202
00:08:01,480 --> 00:08:05,240
INITIALLY, AS A PRIVATE SECTOR

203
00:08:05,240 --> 00:08:06,720
CON TRACKER TO THE OFFICE OF

204
00:08:06,720 --> 00:08:09,840
NAVAL RESEARCH, SHE JOINED THE

205
00:08:09,840 --> 00:08:14,920
NIAID DEA OFFICE OF ACQUISITIONS

206
00:08:14,920 --> 00:08:18,400
IN 2011.

207
00:08:18,400 --> 00:08:19,600
NIAID WELCOMES TWO NEW BRANCH

208
00:08:19,600 --> 00:08:21,760
CHIEFS TO JOINS THE TECHNOLOGY

209
00:08:21,760 --> 00:08:24,520
TRANSFER AND INTELLECTUAL

210
00:08:24,520 --> 00:08:28,520
PROPERTY OFFICE.

211
00:08:28,520 --> 00:08:31,160
Dr. COSSEY MAFUDA IS THE TIP

212
00:08:31,160 --> 00:08:36,160
AND Dr. CHATTERJEE IS THE NEW

213
00:08:36,160 --> 00:08:40,800
CHIEF OF THE BRANCH B.

214
00:08:40,800 --> 00:08:42,520
COSMO SERVED AS THE DIRECTOR OF

215
00:08:42,520 --> 00:08:44,240
THE OFFICE OF PARTNERSHIP AND

216
00:08:44,240 --> 00:08:45,200
BUSINESS DEVELOPMENT AT THE

217
00:08:45,200 --> 00:08:47,880
NATIONAL MEDICAL RESEARCH

218
00:08:47,880 --> 00:08:48,600
CENTER.

219
00:08:48,600 --> 00:08:50,520
PREVIOUSLY, HE WAS A PATENT AND

220
00:08:50,520 --> 00:08:53,480
LICENSING CONSULTANT IN THE FDA

221
00:08:53,480 --> 00:08:55,960
TECHNOLOGY TRANSFER PROGRAM AND

222
00:08:55,960 --> 00:08:58,480
A PATENT IN LICENSING OFFICER AT

223
00:08:58,480 --> 00:09:01,440
THE UNIVERSITY OF MARYLAND,

224
00:09:01,440 --> 00:09:01,920
BALTIMORE.

225
00:09:01,920 --> 00:09:06,160
Dr. CHATTERJEE CAME TO NIAID

226
00:09:06,160 --> 00:09:07,520
FROM THE NCI.

227
00:09:07,520 --> 00:09:10,480
HE WAS A MEMBER OF THE

228
00:09:10,480 --> 00:09:11,000
LEADERSHIP TEAM AND THE

229
00:09:11,000 --> 00:09:12,880
TECHNOLOGY TRANSFER CENTER AND

230
00:09:12,880 --> 00:09:15,040
SERVED AS THE UNIT SUPERVISOR

231
00:09:15,040 --> 00:09:17,400
FOR TECHNOLOGY TRANSFER

232
00:09:17,400 --> 00:09:20,760
OPERATIONS NOT ONLY OF NCI AND

233
00:09:20,760 --> 00:09:25,520
ALSO OF OTHER NIH ENTITIES.

234
00:09:25,520 --> 00:09:28,360
FINALLY, WE ARE PLEASED TO

235
00:09:28,360 --> 00:09:30,000
WELCOME BACK TO NIAID STEPHANIE

236
00:09:30,000 --> 00:09:31,760
HIXSON, THE NEW DIRECTOR OF OUR

237
00:09:31,760 --> 00:09:35,800
OFFICE OF WORKPLACE SOLUTIONS.

238
00:09:35,800 --> 00:09:36,720
STEPHANIE FILLS THE POSITIONS

239
00:09:36,720 --> 00:09:40,320
LEFT BY THE RETIREMENT OF JUDY

240
00:09:40,320 --> 00:09:42,000
YAS KNEE LATE LAST YEAR.

241
00:09:42,000 --> 00:09:44,120
STEPHANIE CAME TO NIH FROM HER

242
00:09:44,120 --> 00:09:45,640
POSITION AS SENIOR DIRECTOR OF

243
00:09:45,640 --> 00:09:56,160
REAL ESTATE AND CONSTRUCTION SHE

244
00:09:56,600 --> 00:09:59,560
PROVIDED 15 YEARS OF DEDICATED

245
00:09:59,560 --> 00:10:01,840
SERVICE TO NIH, INCLUDING,

246
00:10:01,840 --> 00:10:04,600
MANAGING THE DESIGN AND

247
00:10:04,600 --> 00:10:06,120
ACTIVATION OF NIAID'S ON CAMPUS

248
00:10:06,120 --> 00:10:08,440
BIO CONTAINMENT RESEARCH

249
00:10:08,440 --> 00:10:11,720
BUILDING AND MANAGING THE

250
00:10:11,720 --> 00:10:17,120
NIAID'S BSL4 MRI IMAGING

251
00:10:17,120 --> 00:10:17,680
FACILITY.

252
00:10:17,680 --> 00:10:21,360
THROUGHOUT THE YEAR, NIAID HOSTS

253
00:10:21,360 --> 00:10:23,280
MANY INTERNATIONAL DELEGATIONS

254
00:10:23,280 --> 00:10:28,200
WITH WHICH I, AND OTHER STAFF

255
00:10:28,200 --> 00:10:31,920
MEMBERS, MEET.

256
00:10:31,920 --> 00:10:33,360
DURING THE LAST FEW MOVES WE

257
00:10:33,360 --> 00:10:35,800
HAVE COORDINATED VIRTUAL AND

258
00:10:35,800 --> 00:10:37,080
IN-PERSON MEETINGS WITH VISITORS

259
00:10:37,080 --> 00:10:40,080
FROM THE UNITED ARAB EMIRATES,

260
00:10:40,080 --> 00:10:42,360
GERMANY, ITALY, EUROPE, SOUTH

261
00:10:42,360 --> 00:10:46,800
KOREA AND THE UNITED KINGDOM.

262
00:10:46,800 --> 00:10:48,360
THIS SLIDE HIGHLIGHTS JUST A FEW

263
00:10:48,360 --> 00:10:51,680
OF THESE MEETINGS.

264
00:10:51,680 --> 00:10:53,320
PICTURED IN THE UPPER-LEFT OF

265
00:10:53,320 --> 00:10:57,760
THE SLIDE IS PROFESSOR CHRIS

266
00:10:57,760 --> 00:10:59,000
WHITTY THE CHIEF MEDICAL OFFICER

267
00:10:59,000 --> 00:11:00,160
FOR ENGLAND.

268
00:11:00,160 --> 00:11:02,160
WE'VE HAD SEVERAL

269
00:11:02,160 --> 00:11:04,320
REGULARLY-SCHEDULED RECENT

270
00:11:04,320 --> 00:11:05,920
EXCHANGES TO DISCUSS COVID-19

271
00:11:05,920 --> 00:11:11,960
RESEARCH AND CHALLENGES AS WELL

272
00:11:11,960 --> 00:11:12,640
AS THE MONKEYPOX OUTBREAK.

273
00:11:12,640 --> 00:11:15,960
IN THE UPPER-RIGHT OF THE SLIDE,

274
00:11:15,960 --> 00:11:19,440
I AM PICTURED GREETING Dr.

275
00:11:19,440 --> 00:11:23,040
HANCE KLUGE THE WHO REGIONAL

276
00:11:23,040 --> 00:11:25,200
DIRECTOR FOR EUROPE DURING HIS

277
00:11:25,200 --> 00:11:26,840
VISIT TO WASHINGTON IN EARLY

278
00:11:26,840 --> 00:11:27,240
DOUG.

279
00:11:27,240 --> 00:11:31,280
HE AND I DISCUSSED COVID-19

280
00:11:31,280 --> 00:11:33,080
READINESS FOR THE FALL,

281
00:11:33,080 --> 00:11:34,400
MONKEYPOX AND OTHER TOPICS.

282
00:11:34,400 --> 00:11:38,000
IN THE LOWER-RIGHT AREA OF THE

283
00:11:38,000 --> 00:11:39,440
SLIDE, I AM PICTURED WITH A

284
00:11:39,440 --> 00:11:44,840
DELEGATION OF SENIOR UAE HEALTH

285
00:11:44,840 --> 00:11:45,120
OFFICIALS.

286
00:11:45,120 --> 00:11:47,480
NIAID STAFF FROM OUR INTRAMURAL

287
00:11:47,480 --> 00:11:51,560
PROGRAM AND THE VRC JOINED ME IN

288
00:11:51,560 --> 00:11:53,200
DISCUSSING WITH THEM

289
00:11:53,200 --> 00:11:54,040
COLLABORATIVE ACTIVITIES

290
00:11:54,040 --> 00:11:56,560
INCLUDING A JOINT GRANT PROGRAM

291
00:11:56,560 --> 00:12:01,280
THAT WE ARE CO FUNDING WITH UAE

292
00:12:01,280 --> 00:12:01,680
INSTITUTIONS.

293
00:12:01,680 --> 00:12:05,880
THE PHOTO IN THE LOWER-LEFT AREA

294
00:12:05,880 --> 00:12:08,880
OF THE SLIDE SHOW A VIRTUAL

295
00:12:08,880 --> 00:12:12,280
MEETING I ATTENDED JUNE 3

296
00:12:12,280 --> 00:12:14,080
JUNE 30th WITH THE GERMAN

297
00:12:14,080 --> 00:12:21,880
MINISTER OF HEALTH Dr. KARL

298
00:12:21,880 --> 00:12:23,480
LAUTERBACH AND Dr. SAHIN AS

299
00:12:23,480 --> 00:12:24,800
WELL AS THE WHITE HOUSE

300
00:12:24,800 --> 00:12:27,400
CORONAVIRUS RESPONSE COORDINATOR

301
00:12:27,400 --> 00:12:30,840
Dr. JHA TO DISCUSS THE

302
00:12:30,840 --> 00:12:33,320
SCIENTIFIC EVIDENCE FOR GUIDING

303
00:12:33,320 --> 00:12:34,960
VACCINES SELECTION FOR THE FALL

304
00:12:34,960 --> 00:12:38,360
IMMUNIZATION CAMPAIGN.

305
00:12:38,360 --> 00:12:48,800
ON JULY 8th, WE ENTERED INTO A

306
00:12:48,800 --> 00:12:50,440
AGREEMENT WITH . TECHNOLOGY

307
00:12:50,440 --> 00:12:52,160
COMPANY BASED IN CAPE TOWN,

308
00:12:52,160 --> 00:12:56,000
SOUTH AFRICA.

309
00:12:56,000 --> 00:12:57,040
THE MRNA VACCINE CENTER OF

310
00:12:57,040 --> 00:13:00,000
EXCELLENCE AND TRAINING OR THE

311
00:13:00,000 --> 00:13:01,440
TECHNOLOGY TRANSFER HUB PART OF

312
00:13:01,440 --> 00:13:05,360
AN EFFORT LED BY W.H.O. TO BUILD

313
00:13:05,360 --> 00:13:07,360
CAPACITY IN LOW AND MIDDLE

314
00:13:07,360 --> 00:13:11,120
INCOME COUNTRIES TO MAKE mRNA

315
00:13:11,120 --> 00:13:11,400
VACCINES.

316
00:13:11,400 --> 00:13:14,120
THE MUTUALLY BENEFICIAL

317
00:13:14,120 --> 00:13:17,760
COLLABORATION WILL ENABLE

318
00:13:17,760 --> 00:13:23,120
SCIENTISTS AT THE NIAID/VRC AND

319
00:13:23,120 --> 00:13:24,800
AFRIGEN TO SHARE KNOWLEDGE,

320
00:13:24,800 --> 00:13:27,480
EXPERTISE AND DATA ON mRNA

321
00:13:27,480 --> 00:13:28,960
PRODUCTION PROCESSES TO SUPPORT

322
00:13:28,960 --> 00:13:32,840
THEIR RESPECTED MISSIONS FOR THE

323
00:13:32,840 --> 00:13:34,520
VRC TO PRODUCE VACCINES FOR

324
00:13:34,520 --> 00:13:37,400
EARLY-STAGE CLINICAL TRIALS AND

325
00:13:37,400 --> 00:13:41,440
FOR AFRIGEN TO MANUFACTURE

326
00:13:41,440 --> 00:13:45,080
VACCINES AT SCALE.

327
00:13:45,080 --> 00:13:46,800
NOW, I WOULD LIKE TO TAKE A FEW

328
00:13:46,800 --> 00:13:53,480
MINUTES TO UPDATE YOU ON THE NIH

329
00:13:53,480 --> 00:13:53,840
BUDGET.

330
00:13:53,840 --> 00:13:56,080
AS YOU MAY RECALL AT OUR LAST

331
00:13:56,080 --> 00:13:58,480
MEETING, I UPDATED YOU ON THE

332
00:13:58,480 --> 00:14:02,040
FISCAL 2023 PRESIDENT'S BUDGET

333
00:14:02,040 --> 00:14:04,960
RELEASED ON MARCH 28th.

334
00:14:04,960 --> 00:14:07,480
SINCE THEN, THE HOUSE AND SENATE

335
00:14:07,480 --> 00:14:11,360
HAVE BOTH RELEASED DRAFT BUDGETS

336
00:14:11,360 --> 00:14:12,320
FOR NIH.

337
00:14:12,320 --> 00:14:16,600
THE OVER ALL PROPOSAL INCREASED

338
00:14:16,600 --> 00:14:19,680
FOR NIH IN THE BOTTOM-MIDDLE OF

339
00:14:19,680 --> 00:14:25,320
THE SLIDE IS 5.5% UNDER THE

340
00:14:25,320 --> 00:14:29,440
HOUSE BILL, AND 6.6% ON THE

341
00:14:29,440 --> 00:14:32,760
RIGHT LOWER PANEL FOR THE SENNAL

342
00:14:32,760 --> 00:14:34,160
BILL WITH MOST INSTITUTES

343
00:14:34,160 --> 00:14:38,080
RECEIVING AN INCREASE OF 2% ON

344
00:14:38,080 --> 00:14:39,400
BOTH BILLS.

345
00:14:39,400 --> 00:14:41,760
NOTABLY, THE HOUSE BILL PROPOSES

346
00:14:41,760 --> 00:14:51,240
LARGER FUNDING INCREASES THAN

347
00:14:51,240 --> 00:14:52,400
MOST INSTITUTES INCLUDING THE

348
00:14:52,400 --> 00:14:52,600
NIAID.

349
00:14:52,600 --> 00:14:54,080
THE HOUSE AND SENATE BILLS HAVE

350
00:14:54,080 --> 00:14:55,840
A DIFFERENT STRATEGY FOR FUNDING

351
00:14:55,840 --> 00:14:58,240
THE ADVANCED RESEARCH PROJECTS

352
00:14:58,240 --> 00:15:01,280
AGENCIES FOR HEALTH OR ARPA-H.

353
00:15:01,280 --> 00:15:06,960
THIS IS AN INITIATIVE CREATE

354
00:15:06,960 --> 00:15:09,000
TODAY SPEED TRANSFORMATION IN

355
00:15:09,000 --> 00:15:10,320
THE HEALTH RESEARCH AND THE

356
00:15:10,320 --> 00:15:12,320
APPLICATION AND IMPLEMENTATION

357
00:15:12,320 --> 00:15:12,920
OF HEALTH BREAKTHROUGHS.

358
00:15:12,920 --> 00:15:18,840
UNDER THE HOUSE BILL, ARPA-H

359
00:15:18,840 --> 00:15:20,400
WOULD RESIDE OUTSIDE OF THE NIH,

360
00:15:20,400 --> 00:15:26,840
SPECIFICALLY WITHIN THE HHS

361
00:15:26,840 --> 00:15:28,000
OFFICE OF THE SECRETARY WITH AN

362
00:15:28,000 --> 00:15:30,280
INITIAL BUDGET OF $2.75 BILLION.

363
00:15:30,280 --> 00:15:36,800
THE SENATE BILL INCORPORATES

364
00:15:36,800 --> 00:15:43,800
ARPA-H WITHIN NIH WITH A BUDGET

365
00:15:43,800 --> 00:15:44,240
OF $1 BILLION.

366
00:15:44,240 --> 00:15:45,680
THE CONFERENCE COMMITTEE IS IN

367
00:15:45,680 --> 00:15:47,440
THE PROCESS OF IRONING OUT THE

368
00:15:47,440 --> 00:15:49,320
DIFFERENCES CONTAINED IN THE

369
00:15:49,320 --> 00:15:53,840
HOUSE VERSUS THE SENATE BILLS

370
00:15:53,840 --> 00:15:55,360
BEFORE IT SENDS THE BUDGET

371
00:15:55,360 --> 00:15:58,000
PACKAGE TO THE PRESIDENT FOR HIS

372
00:15:58,000 --> 00:15:58,280
SIGNATURE.

373
00:15:58,280 --> 00:15:59,760
GIVEN WHERE WE ARE IN THE BUDGET

374
00:15:59,760 --> 00:16:03,400
PROCESS, WE EXPECT TO BEGIN

375
00:16:03,400 --> 00:16:05,680
FISCAL '23 UNDER A CONTINUING

376
00:16:05,680 --> 00:16:10,400
RESOLUTION OR A CR.

377
00:16:10,400 --> 00:16:11,360
THIS IS NOTHING NEW.

378
00:16:11,360 --> 00:16:13,160
WE HAVE BEGUN THE FISCAL YEAR

379
00:16:13,160 --> 00:16:18,520
UNDER CR EVERY FISCAL YEAR SINCE

380
00:16:18,520 --> 00:16:18,920
1998.

381
00:16:18,920 --> 00:16:23,840
UNTIL A FINAL FY23 BUDGET IS

382
00:16:23,840 --> 00:16:25,960
PASSED, WE WILL MAINTAIN A

383
00:16:25,960 --> 00:16:29,520
CONSERVATIVE POSTURE IN SETTING

384
00:16:29,520 --> 00:16:32,480
PAY LINES AND PROGRAM LEVELS SO

385
00:16:32,480 --> 00:16:35,320
WE MAINTAIN THE FLEXIBILITY TO

386
00:16:35,320 --> 00:16:37,320
ADJUST PROGRAMS TO EFFECTIVELY

387
00:16:37,320 --> 00:16:41,520
OPERATE WITHIN THE FINAL BUDGET

388
00:16:41,520 --> 00:16:45,640
LEVEL WHICH WE DO NOT ME AT THIS

389
00:16:45,640 --> 00:16:46,040
POINT.

390
00:16:46,040 --> 00:16:48,840
THIS SLIDE SHOWS THE NIAID

391
00:16:48,840 --> 00:16:49,560
FINANCIAL MANAGEMENT PLAN FOR

392
00:16:49,560 --> 00:16:52,400
THE FISCAL '23 BUDGET.

393
00:16:52,400 --> 00:16:55,440
OUR RO1 PAYLINES FOR ESTABLISHED

394
00:16:55,440 --> 00:17:06,360
AND NEW P.I.s ARE AT THE TENTH .

395
00:17:06,640 --> 00:17:08,240
COMPETING UNSOLACATED AWARDS AS

396
00:17:08,240 --> 00:17:10,200
WELL AS NON COMPETING GRANTS AND

397
00:17:10,200 --> 00:17:13,400
RND AWARDS WILL INCUR NEW

398
00:17:13,400 --> 00:17:15,080
PROBLEMATIC ADJUSTMENTS AND

399
00:17:15,080 --> 00:17:16,600
COMPETING RESEARCH INITIATIVES

400
00:17:16,600 --> 00:17:20,560
HAVE BEEN CUT BY UP TO 20% TO

401
00:17:20,560 --> 00:17:21,880
SUSTAINED NEW INVESTIGATOR

402
00:17:21,880 --> 00:17:25,040
INITIATED AWARDS.

403
00:17:25,040 --> 00:17:27,160
WE ESTIMATE THAT OVER ALL

404
00:17:27,160 --> 00:17:31,240
SUCCESS RATES WILL BE 18 TO 22%

405
00:17:31,240 --> 00:17:35,480
SIMILAR TO THAT OF 2022.

406
00:17:35,480 --> 00:17:38,240
NOW AN IMPORTANT ASPECT OF OUR

407
00:17:38,240 --> 00:17:39,880
APPROPRIATION IS TO SUMMARIZE

408
00:17:39,880 --> 00:17:45,040
THE PREPORTION THAT CONGRESS HAS

409
00:17:45,040 --> 00:17:46,520
EARMARKED FOR NIAID TO SPEND ON

410
00:17:46,520 --> 00:17:49,240
SPECIFIC DISEASE AREAS.

411
00:17:49,240 --> 00:17:52,080
WE APPRECIATE THE ADDITIONAL

412
00:17:52,080 --> 00:17:53,320
FUNDING.

413
00:17:53,320 --> 00:17:56,800
HOWEVER, EARMARKS LIMIT OUR

414
00:17:56,800 --> 00:18:01,880
FLEXIBILITY TO SUPPORT

415
00:18:01,880 --> 00:18:02,880
INVESTIGATOR-INITIATED PROJECT

416
00:18:02,880 --> 00:18:06,960
AND OTHER IMPORTANT NIAID

417
00:18:06,960 --> 00:18:08,160
RESEARCH PRIORITIES.

418
00:18:08,160 --> 00:18:11,080
THE ATTACHED TABLE SHOWS THE

419
00:18:11,080 --> 00:18:13,680
COMPONENTS OF OUR BASE AND

420
00:18:13,680 --> 00:18:16,240
EARMARKED BUDGETS FROM FISCAL

421
00:18:16,240 --> 00:18:18,120
2022 COMPARED TO PROPOSES IN THE

422
00:18:18,120 --> 00:18:22,360
HOUSE AND SENATE BILLS FOR

423
00:18:22,360 --> 00:18:22,960
FISCAL '23.

424
00:18:22,960 --> 00:18:26,160
BOTH THE HOUSE AND SENATE BILLS

425
00:18:26,160 --> 00:18:29,480
PROPOSE INCREASING THE EARMARKS

426
00:18:29,480 --> 00:18:35,520
ALLOCATIONS FOR ANTIMICROBIAL

427
00:18:35,520 --> 00:18:36,840
RESISTANCE AND RESOURCE AND

428
00:18:36,840 --> 00:18:37,080
VACCINES.

429
00:18:37,080 --> 00:18:39,640
THEY MAINTAIN THE SAME BUDGET

430
00:18:39,640 --> 00:18:42,200
ALLOCATIONS FOR 23 REGIONAL BIO

431
00:18:42,200 --> 00:18:45,000
CONTAINMENT LABS THAT WE

432
00:18:45,000 --> 00:18:46,640
INITIALLY FUNDED IN FISCAL 2003

433
00:18:46,640 --> 00:18:49,120
TO PREVENT, PREPARE FOR AND

434
00:18:49,120 --> 00:18:53,000
RESPOND TO INFECTIOUS DISEASES

435
00:18:53,000 --> 00:18:53,280
OUTBREAKS.

436
00:18:53,280 --> 00:18:56,240
THE HOUSE BILL ALSO PRIORITIZES

437
00:18:56,240 --> 00:18:58,840
FUNDING TO SUPPORT THE

438
00:18:58,840 --> 00:19:00,280
CONSORTIUM OF FOOD ALLERGY

439
00:19:00,280 --> 00:19:02,720
RESEARCH AND HEALTH DISPARITIES

440
00:19:02,720 --> 00:19:03,040
RESEARCH.

441
00:19:03,040 --> 00:19:05,280
AS I NOTED BEFORE, WE WILL HAVE

442
00:19:05,280 --> 00:19:07,840
TO WAIT UNTIL THE HOUSE AND

443
00:19:07,840 --> 00:19:10,240
SENATE RESOLVE DIFFERENCES

444
00:19:10,240 --> 00:19:12,440
CONTAINED IN THEIR BILLS TO SEE

445
00:19:12,440 --> 00:19:17,680
THE FINAL PREPORTION OF FUNDING

446
00:19:17,680 --> 00:19:18,480
DIRECTED TO EARMARKS.

447
00:19:18,480 --> 00:19:20,080
NOW, LET ME TAKE A FEW MOMENTS

448
00:19:20,080 --> 00:19:24,120
TO BRIEFLY SUMMARIZE FUNDING

449
00:19:24,120 --> 00:19:25,760
PROVIDED TO NIAID TO RESPOND

450
00:19:25,760 --> 00:19:28,520
SPECIFICALLY TO THE COVID-19

451
00:19:28,520 --> 00:19:33,440
PANDEMIC AND CORONAVIRUSES.

452
00:19:33,440 --> 00:19:35,880
THE TOP HALF OF THE TABLE RECAPS

453
00:19:35,880 --> 00:19:36,800
FUNDING BY NIAID AND THE NIH

454
00:19:36,800 --> 00:19:39,800
SINCE MARCH OF 2020 THROUGH FOUR

455
00:19:39,800 --> 00:19:41,720
SUPPLEMENTAL APPROPRIATIONS.

456
00:19:41,720 --> 00:19:44,360
THESE FUNDS ARE AVAILABLE TO USE

457
00:19:44,360 --> 00:19:51,120
UNTIL SEPTEMBER THE 30th,

458
00:19:51,120 --> 00:19:52,400
2024.

459
00:19:52,400 --> 00:19:53,720
NIAID'S $1.5 BILLION IN FUNDING

460
00:19:53,720 --> 00:19:56,120
SUPPORTS A BROAD ARRAY OF

461
00:19:56,120 --> 00:19:57,440
INTRAMURAL AND EXTRAMURAL

462
00:19:57,440 --> 00:19:59,800
RESEARCH TO IMPROVE OUR

463
00:19:59,800 --> 00:20:02,960
FUNDAMENTAL UNDERSTANDING OF

464
00:20:02,960 --> 00:20:04,200
SARS-CoV-2, AND COVID-19

465
00:20:04,200 --> 00:20:06,960
DISEASE PROGRESSION, OUTCOMES,

466
00:20:06,960 --> 00:20:08,720
RECOVERY, AND TO ADVANCE THE

467
00:20:08,720 --> 00:20:12,440
DEVELOPMENT OF SAFE AND

468
00:20:12,440 --> 00:20:15,000
EFFECTIVE VACCINES, THERAPEUTICS

469
00:20:15,000 --> 00:20:15,920
AND DIAGNOSTICS.

470
00:20:15,920 --> 00:20:18,400
WE HAVE AWARDED OR COMMITTED

471
00:20:18,400 --> 00:20:22,440
MORE THAN 95% OF THESE FUNDS.

472
00:20:22,440 --> 00:20:25,680
NIH IS $3.3 BILLION IN ADDITION

473
00:20:25,680 --> 00:20:31,000
TO COMPLIMENTING OUR ACTIVITIES

474
00:20:31,000 --> 00:20:32,080
INCLUDES $1.9 BILLION TO ADVANCE

475
00:20:32,080 --> 00:20:34,120
RESEARCH TO DEVELOP AND VAL DADE

476
00:20:34,120 --> 00:20:39,520
NEW AS SAYS AND RETOOL EXISTING

477
00:20:39,520 --> 00:20:40,520
DIAGNOSTIC PLATFORMS THROUGH

478
00:20:40,520 --> 00:20:43,440
PROGRAMS SUCH AS THE RAPID

479
00:20:43,440 --> 00:20:49,040
ACCELERATION OF RADX ALSO

480
00:20:49,040 --> 00:20:54,760
INCLUDED IN THE $3.3 BILLION IS

481
00:20:54,760 --> 00:20:56,600
$1.15 BILLION FOR NIH TO SUPPORT

482
00:20:56,600 --> 00:20:58,000
RESEARCH INTO THE PROLONGED

483
00:20:58,000 --> 00:21:00,840
HEALTH CONSEQUENCES OF

484
00:21:00,840 --> 00:21:02,320
SARS-CoV-2 INFECTION OR ALSO

485
00:21:02,320 --> 00:21:05,920
KNOWN AS LONG-COVID.

486
00:21:05,920 --> 00:21:07,720
THE BOTTOM HALF OF THE TABLE

487
00:21:07,720 --> 00:21:10,680
NOTES FUNDING PROVIDED TO DATE

488
00:21:10,680 --> 00:21:16,480
BY THE HHS OFFICE OF THE

489
00:21:16,480 --> 00:21:17,600
SECRETARY TO NIAID TO EXECUTE

490
00:21:17,600 --> 00:21:20,000
NIH'S ACCELERATING COVID-19

491
00:21:20,000 --> 00:21:22,480
THERAPEUTIC INTERVENTIONS AND

492
00:21:22,480 --> 00:21:28,440
VACCINES OR ACTIVE PARTNERSHIP.

493
00:21:28,440 --> 00:21:30,720
ACTIVE WORKS WITH THE HHS

494
00:21:30,720 --> 00:21:32,200
COORDINATION OPERATIONS AND A

495
00:21:32,200 --> 00:21:35,880
RESPONSE ELEMENT OR H-CORE

496
00:21:35,880 --> 00:21:39,480
PREVIOUSLY KNOWN AS

497
00:21:39,480 --> 00:21:42,720
COUNTERMEASURES ACCELERATION

498
00:21:42,720 --> 00:21:44,760
GROUP AND OPERATION WARP SPEED.

499
00:21:44,760 --> 00:21:46,560
WE DO THIS TO COORDINATE THE

500
00:21:46,560 --> 00:21:47,280
GOVERNMENT'S PANDEMIC RESPONSE

501
00:21:47,280 --> 00:21:51,000
AND INTERACT WITH THE PRIVATE

502
00:21:51,000 --> 00:21:53,280
SECTOR TO ACCELERATE THE

503
00:21:53,280 --> 00:21:55,960
DEVELOPMENT, MANUFACTURING AND

504
00:21:55,960 --> 00:22:01,600
DISTRIBUTION OF COVID-19

505
00:22:01,600 --> 00:22:02,680
VACCINES, THERAPEUTICS AND

506
00:22:02,680 --> 00:22:04,480
DIAGNOSTICS.

507
00:22:04,480 --> 00:22:05,480
THE $2.5 BILLION FOR NIAID

508
00:22:05,480 --> 00:22:07,080
INCLUDES SUPPORT FOR PHASE 3

509
00:22:07,080 --> 00:22:10,000
CLINICAL TRIALS OF FIVE

510
00:22:10,000 --> 00:22:11,440
CANDIDATE VACCINES, AS WELL AS

511
00:22:11,440 --> 00:22:15,560
VACCINES STUDIES AND SPECIAL

512
00:22:15,560 --> 00:22:16,840
POPULATIONS.

513
00:22:16,840 --> 00:22:18,840
FUNDING ALSO SUPPORTS CLINICAL

514
00:22:18,840 --> 00:22:21,800
TRIALS TO EVALUATE COVID-19

515
00:22:21,800 --> 00:22:24,440
THERAPEUTICS AND INCLUDING THE

516
00:22:24,440 --> 00:22:27,520
ACT OF TWO STUDY AND ADAPTIVE

517
00:22:27,520 --> 00:22:30,200
TRIAL TESTING INVESTIGATIONAL

518
00:22:30,200 --> 00:22:31,600
AGENTS AND NON HOSPITALIZED

519
00:22:31,600 --> 00:22:33,240
ADULTS WITH MILD TO MODERATE

520
00:22:33,240 --> 00:22:35,480
COVID-19 SYMPTOMS.

521
00:22:35,480 --> 00:22:38,760
IN ADDITION, THESE FUNDS SUPPORT

522
00:22:38,760 --> 00:22:41,480
COMPREHENSIVE REAL-TIME RISK

523
00:22:41,480 --> 00:22:43,880
ASSESSMENT OF EMERGING MUTATIONS

524
00:22:43,880 --> 00:22:45,640
AND EFFORTS TO RAPIDLY

525
00:22:45,640 --> 00:22:48,440
CHARACTERIZE EMERGING VARIANTS

526
00:22:48,440 --> 00:22:52,840
AND ACTIVELY MONITORING THE

527
00:22:52,840 --> 00:22:54,440
IMPACT ON SARS-CoV-2 VACCINES

528
00:22:54,440 --> 00:22:57,320
AND THERAPEUTICS THROUGH THE

529
00:22:57,320 --> 00:23:00,800
SARS-CoV-2 ASSESSMENT OF VIRAL

530
00:23:00,800 --> 00:23:05,280
EVOLUTION OR SAVE PROGRAM.

531
00:23:05,280 --> 00:23:09,480
NIAID HAS INVESTED $0.7 BILLION

532
00:23:09,480 --> 00:23:12,760
THROUGH THE AMERICAN RESCUE PLAN

533
00:23:12,760 --> 00:23:16,920
TO IMPLEMENT THE ANTIVIRAL

534
00:23:16,920 --> 00:23:18,160
PROGRAM FOR PANDEMICS WHICH

535
00:23:18,160 --> 00:23:20,000
INCLUDES AWARDING ABOUT

536
00:23:20,000 --> 00:23:22,040
$600 MILLION TO NINE ANTIVIRAL

537
00:23:22,040 --> 00:23:24,840
DRUG DISCOVERY OR AVID CENTERS

538
00:23:24,840 --> 00:23:27,320
AND THESE CENTERS WILL CONDUCT

539
00:23:27,320 --> 00:23:29,440
INNOVATIVE, MULTI-DISCIPLINARY

540
00:23:29,440 --> 00:23:33,680
RESEARCH TO DEVELOP CANDIDATE

541
00:23:33,680 --> 00:23:34,840
COVID-19 ANTIVIRALS AND

542
00:23:34,840 --> 00:23:36,200
ESPECIALLY THOSE THAT CAN BE

543
00:23:36,200 --> 00:23:39,160
TAKEN IN AN OUT PATIENT SETTING.

544
00:23:39,160 --> 00:23:41,400
AS WELL AS ANTIVIRALS TARGETING

545
00:23:41,400 --> 00:23:44,280
SPECIFIC VIRAL FAMILIES WITH

546
00:23:44,280 --> 00:23:49,360
HYPO TEN SHIGH POTENTIAL TO CAUA

547
00:23:49,360 --> 00:23:50,200
PANDEMIC IN THE FUTURE.

548
00:23:50,200 --> 00:23:53,000
WE'RE UNCERTAIN ABOUT THE SOURCE

549
00:23:53,000 --> 00:23:54,920
OF FUTURE-YEAR FUNDING TO

550
00:23:54,920 --> 00:23:59,280
CONTINUE THE ANTIVIRAL PROGRAM

551
00:23:59,280 --> 00:24:00,680
FOR PANDEMICS, WE'VE BEEN

552
00:24:00,680 --> 00:24:02,600
WORKING ON POTENTIAL FUNDING

553
00:24:02,600 --> 00:24:04,960
SOLUTIONS TO SUSTAIN THIS VERY

554
00:24:04,960 --> 00:24:11,400
IMPORTANT INITIATIVE.

555
00:24:11,400 --> 00:24:13,640
FOR EXAMPLE, A PARTIAL SOLUTION

556
00:24:13,640 --> 00:24:16,840
IS THE SEPTEMBER 2nd PROPOSED

557
00:24:16,840 --> 00:24:19,960
SUPPLEMENT THE BUDGET TO

558
00:24:19,960 --> 00:24:21,480
CONGRESS FOR FISCAL 2023.

559
00:24:21,480 --> 00:24:23,800
WHICH INCLUDES $22 BILLION TO

560
00:24:23,800 --> 00:24:28,240
OVER ON GOING NEEDS ASSOCIATED

561
00:24:28,240 --> 00:24:30,120
WITH THE COVID-19 PANDEMIC.

562
00:24:30,120 --> 00:24:32,560
INCLUDED IN THAT PROPOSAL WAS

563
00:24:32,560 --> 00:24:34,960
$8 BILLION FOR PROJECT COVID

564
00:24:34,960 --> 00:24:37,480
SHIELD, TO DEVELOP AND LICENSE

565
00:24:37,480 --> 00:24:40,280
THE VACCINES AND THERAPEUTICS

566
00:24:40,280 --> 00:24:46,240
NEEDED TO BETTER ADDRESS THE

567
00:24:46,240 --> 00:24:48,640
EMERGENCE OF NEW STRAINS OF

568
00:24:48,640 --> 00:24:48,960
SARS-CoV-2.

569
00:24:48,960 --> 00:24:50,920
WE WILL NEED TO EVADE FOR

570
00:24:50,920 --> 00:24:51,880
CONGRESS TO DELIBERATE THIS

571
00:24:51,880 --> 00:24:53,400
REQUEST BUT AS MANY OF YOU HAVE

572
00:24:53,400 --> 00:24:55,440
HEARD, THE REPUBLICAN IN

573
00:24:55,440 --> 00:24:56,520
CONGRESS HAVE MADE IT CLEAR

574
00:24:56,520 --> 00:25:01,560
THEY'RE NOT SYMPATHETIC TO THIS

575
00:25:01,560 --> 00:25:03,960
REQUEST FOR SUPPLEMENTAL

576
00:25:03,960 --> 00:25:04,200
FUNDING.

577
00:25:04,200 --> 00:25:08,480
THIS SLIDE SUMMARIZES THE NIAID

578
00:25:08,480 --> 00:25:11,160
BUDGET FOR MONKEYPOX IN FISCAL

579
00:25:11,160 --> 00:25:15,200
2021, 2022 AND 2023.

580
00:25:15,200 --> 00:25:17,600
FISCAL 2021 FUNDING REFLECTS

581
00:25:17,600 --> 00:25:20,400
NIAID'S PREPAREDNESS EFFORTS TO

582
00:25:20,400 --> 00:25:23,120
STUDY HIGH-CONSEQUENCE PATHOGENS

583
00:25:23,120 --> 00:25:27,840
IN KEY INTERNATIONAL LOCATIONS

584
00:25:27,840 --> 00:25:29,240
WHERE THEY ARE ENDEMIC AND

585
00:25:29,240 --> 00:25:33,720
INCLUDES A COLLABORATION WITH

586
00:25:33,720 --> 00:25:35,880
THE RESEARCH BIOMEDICAL OF THE

587
00:25:35,880 --> 00:25:37,640
DEMOCRATIC REPUBLIC OF THE CONGO

588
00:25:37,640 --> 00:25:39,400
OR DRC.

589
00:25:39,400 --> 00:25:43,200
WHICH EXPECTS TO SOON BEGIN A

590
00:25:43,200 --> 00:25:45,600
DOUBLE-BLIND PLACEBO-CONTROLLED

591
00:25:45,600 --> 00:25:48,080
TRIAL OF THE SAFETY AND THE

592
00:25:48,080 --> 00:25:53,640
EFFICACY OF TPOX FOR TREATING

593
00:25:53,640 --> 00:25:57,560
ADULT AND PEDIATRIC PATIENTS

594
00:25:57,560 --> 00:25:59,480
DIAGNOSIS WITH MONKEYPOX.

595
00:25:59,480 --> 00:26:01,320
SINCE MONKEYPOX WAS DECLARED A

596
00:26:01,320 --> 00:26:03,120
PUBLIC-HEALTH EMERGENCY IN THE

597
00:26:03,120 --> 00:26:06,280
UNITED STATES IN AUGUST, WE HAVE

598
00:26:06,280 --> 00:26:11,200
EXPANDED OUR RESEARCH ON THE

599
00:26:11,200 --> 00:26:14,680
BIOLOGY AND CLINICAL

600
00:26:14,680 --> 00:26:15,480
MANIFESTATIONS OF MONKEYPOX'S

601
00:26:15,480 --> 00:26:16,600
INFECTION AS WELL AS STUDIES OF

602
00:26:16,600 --> 00:26:18,800
EXISTING AND POTENTIAL

603
00:26:18,800 --> 00:26:23,040
INTERVENTIONS TO DIAGNOSE TREAT

604
00:26:23,040 --> 00:26:26,600
AND PREVENT MONKEYPOX FISCAL

605
00:26:26,600 --> 00:26:28,240
2022 INVESTMENTS REFLECT THE

606
00:26:28,240 --> 00:26:31,560
ABOVE RESEARCH AREAS INCLUDING

607
00:26:31,560 --> 00:26:34,280
TWO NOTABLE CLINICAL TRIALS.

608
00:26:34,280 --> 00:26:39,160
ONE IS A PHASE 3 RANDOMIZED

609
00:26:39,160 --> 00:26:41,200
PLACEBO CONTROL DOUBLE BLIND

610
00:26:41,200 --> 00:26:42,280
TRIAL FOR THE TREATMENT OF

611
00:26:42,280 --> 00:26:43,240
MONKEYPOX IN OUT PATIENT

612
00:26:43,240 --> 00:26:47,320
SETTINGS IN THE UNITED STATES

613
00:26:47,320 --> 00:26:48,560
THROUGHOUT AIDS CLINICAL TRIAL

614
00:26:48,560 --> 00:26:48,960
GROUP.

615
00:26:48,960 --> 00:26:52,200
THE SECOND, SAY CLINICAL STUDY

616
00:26:52,200 --> 00:26:55,800
OF GINIOS VACCINE AT LOWER DOSE

617
00:26:55,800 --> 00:26:58,320
AND BY A DIFFERENT ROUTES OF

618
00:26:58,320 --> 00:27:00,200
INOCULATION IN ADULTS 18 YEARS

619
00:27:00,200 --> 00:27:06,080
OF AGE OR OLDER, WHO ARE AT

620
00:27:06,080 --> 00:27:08,080
HIGH-RISK FOR MONKEYPOX

621
00:27:08,080 --> 00:27:08,360
INFECTION.

622
00:27:08,360 --> 00:27:09,640
WE ARE CURRENTLY WORKING WITH

623
00:27:09,640 --> 00:27:11,520
THE EXECUTIVE BRANCH ON

624
00:27:11,520 --> 00:27:14,280
FORMULATING RESEARCH NEEDS AND

625
00:27:14,280 --> 00:27:19,040
IDENTIFYING FUNDING SOURCES FOR

626
00:27:19,040 --> 00:27:21,400
FISCAL 2023 MONKEYPOX RESEARCH.

627
00:27:21,400 --> 00:27:24,200
NOTE, THAT ON SEPTEMBER 2nd,

628
00:27:24,200 --> 00:27:28,400
THE ADMINISTRATION ANNOUNCED ITS

629
00:27:28,400 --> 00:27:29,400
FISCAL 2023 SUPPLEMENTAL BUDGET

630
00:27:29,400 --> 00:27:33,280
REQUEST OF $4.5 BILLION TO

631
00:27:33,280 --> 00:27:35,280
ADDRESS THE CURRENT MONKEYPOX

632
00:27:35,280 --> 00:27:37,520
OUTBREAKS INCLUDING IN THAT

633
00:27:37,520 --> 00:27:40,480
FIGURE, IS CLOSE TO $200 MILLION

634
00:27:40,480 --> 00:27:42,680
TO HHS FOR HIGH-PRIORITY

635
00:27:42,680 --> 00:27:44,760
RESEARCH AND DEVELOPMENT.

636
00:27:44,760 --> 00:27:48,720
INCLUDING THE EVOLUTION OF

637
00:27:48,720 --> 00:27:49,240
VACCINES EFFECTIVENESS IN

638
00:27:49,240 --> 00:27:50,960
SPECIAL POPULATIONS AND THE

639
00:27:50,960 --> 00:27:54,000
DEVELOPMENT OF RAPID DIAGNOSTIC

640
00:27:54,000 --> 00:27:54,560
TESTS.

641
00:27:54,560 --> 00:28:02,240
THE BALL IS NOW IN CONGRESS'

642
00:28:02,240 --> 00:28:02,600
COURT.

643
00:28:02,600 --> 00:28:05,480
NOW LET ME MOVE ON TO DISCUSS

644
00:28:05,480 --> 00:28:12,080
SEVERAL ITEMS OF LEGISLATIVE

645
00:28:12,080 --> 00:28:12,720
INTERESTS.

646
00:28:12,720 --> 00:28:13,880
NIAID-SUPPORTED RESEARCH,

647
00:28:13,880 --> 00:28:15,440
INCLUDING OUR EFFORTS TO BETTER

648
00:28:15,440 --> 00:28:18,520
UNDERSTAND TREAT AND PREVENT

649
00:28:18,520 --> 00:28:21,920
COVID-19 AND POST ACUTE SEE

650
00:28:21,920 --> 00:28:23,640
QUELL A OF COVID KNOWN AS

651
00:28:23,640 --> 00:28:25,360
LONG-COVID, REMAIN TOPICS OF

652
00:28:25,360 --> 00:28:28,280
GREAT INTEREST TO THE CONGRESS.

653
00:28:28,280 --> 00:28:32,400
ON JUNE 16th, I TESTIFIED AT A

654
00:28:32,400 --> 00:28:35,240
SENATE HEALTH EDUCATION LABOR

655
00:28:35,240 --> 00:28:39,000
AND PENSIONS KNOWN AS THE HELP

656
00:28:39,000 --> 00:28:40,560
COMMITTEE HEARING ENTITLED "AN

657
00:28:40,560 --> 00:28:43,480
UPDATE ON THE ON GOING FEDERAL

658
00:28:43,480 --> 00:28:46,360
RESPONSE TO COVID-19 CURRENT

659
00:28:46,360 --> 00:28:50,400
STATUS AND FUTURE PLANNING" THE

660
00:28:50,400 --> 00:28:53,440
ASSIST APARASSISTANT PREPAREDNEE

661
00:28:53,440 --> 00:28:56,960
AND MY COLLEAGUES FROM CDC AND

662
00:28:56,960 --> 00:28:59,160
FDA ALSO PARTICIPATED.

663
00:28:59,160 --> 00:29:01,960
AS MANY OF YOU ARE AWARE IN

664
00:29:01,960 --> 00:29:05,160
JUNE, I TESTED POSITIVE FOR

665
00:29:05,160 --> 00:29:06,960
COVID-19, SO I JOINED THE

666
00:29:06,960 --> 00:29:10,640
HEARING VIRTUALLY WHILE IN

667
00:29:10,640 --> 00:29:12,080
ISOLATION SHOWN HERE DOING ZOOM

668
00:29:12,080 --> 00:29:14,640
FROM MY OFFICE.

669
00:29:14,640 --> 00:29:17,480
THE HEARING WAS AN IMPORTANT

670
00:29:17,480 --> 00:29:18,400
OPPORTUNITY TO DISCUSS SOME OF

671
00:29:18,400 --> 00:29:21,680
THE UNIQUE WAYS THE COVID-19

672
00:29:21,680 --> 00:29:25,040
PANDEMIC HAS CHANGED HOW WE LIVE

673
00:29:25,040 --> 00:29:27,760
AND WORK AND EMPHASIZING THAT

674
00:29:27,760 --> 00:29:29,200
ADDITIONAL EFFORTS ARE NEEDED TO

675
00:29:29,200 --> 00:29:31,800
FULLY CURB THE PANDEMIC.

676
00:29:31,800 --> 00:29:34,160
THE COMMITTEE WAS ESPECIALLY

677
00:29:34,160 --> 00:29:35,800
INTERESTED IN OUR ON GOING

678
00:29:35,800 --> 00:29:38,600
EFFORTS TO BETTER UNDERSTAND AND

679
00:29:38,600 --> 00:29:41,440
TREAT LONG COVID AS WELL AS OUR

680
00:29:41,440 --> 00:29:43,400
PANDEMIC PREPAREDNESS EFFORTS.

681
00:29:43,400 --> 00:29:45,960
I SPOKE ABOUT OUR ANTIVIRAL

682
00:29:45,960 --> 00:29:47,160
PROGRAM FOR PANDEMIC AND

683
00:29:47,160 --> 00:29:50,240
INCLUDING OUR ANTIVIRAL DRUG

684
00:29:50,240 --> 00:29:51,760
DISCOVERY CENTERS TO DEVELOP

685
00:29:51,760 --> 00:29:53,080
THERAPEUTICS THAT COULD BE

686
00:29:53,080 --> 00:29:56,280
UTILIZED DURING A PANDEMIC.

687
00:29:56,280 --> 00:29:59,320
I ALSO STRESS THE IMPORTANCE OF

688
00:29:59,320 --> 00:30:03,720
INVESTING IN PANDEMIC PREPARED

689
00:30:03,720 --> 00:30:04,880
NESTOR ABLE TO QUICKLY RESPONSE

690
00:30:04,880 --> 00:30:09,600
TO THE INEVITABLE NEXT THREAT.

691
00:30:09,600 --> 00:30:12,200
I WANT TO ACKNOWLEDGE ON THIS

692
00:30:12,200 --> 00:30:17,040
BUSY SLIDE, THE NIAID STAFF WHO

693
00:30:17,040 --> 00:30:24,480
ARE PARTICIPATE ON MY BEHALF

694
00:30:24,480 --> 00:30:25,800
INCLUDING APPROPRIATION STAFF.

695
00:30:25,800 --> 00:30:27,360
THESE EVENTS, AS OUTLINED ON

696
00:30:27,360 --> 00:30:29,720
THIS SLIDE, HIGHLIGHT THE

697
00:30:29,720 --> 00:30:31,720
CONTINUED INTEREST OF CONGRESS

698
00:30:31,720 --> 00:30:37,080
IN THE BROADER NIAID RESEARCH

699
00:30:37,080 --> 00:30:42,800
PORTFOLIO AS WELL AS OUR EFFORTS

700
00:30:42,800 --> 00:30:45,120
TO ADDRESS COVID-19 AND ENHANCE

701
00:30:45,120 --> 00:30:46,320
OUR PREPAREDNESS.

702
00:30:46,320 --> 00:30:49,440
I WOULD LIKE TO TAKE A MOMENT TO

703
00:30:49,440 --> 00:30:51,200
NOW REFLECT ON THE LATE

704
00:30:51,200 --> 00:30:55,680
CONGRESSMAN JOHN PORTER.

705
00:30:55,680 --> 00:30:56,960
A TREASURED FRIEND OF NIH WHO

706
00:30:56,960 --> 00:31:00,040
PASSED AWAY SHORTLY AFTER THE

707
00:31:00,040 --> 00:31:04,360
COUNCIL LAST MET IN JUNE

708
00:31:04,360 --> 00:31:05,960
CONGRESSMAN PORTER SERVED AS THE

709
00:31:05,960 --> 00:31:10,320
U.S. REPRESENTATIVE FOR THE

710
00:31:10,320 --> 00:31:20,600
TENTH DIRECTING HE CHAIRED THE

711
00:31:20,600 --> 00:31:21,720
SUBCOMMITTEE ON LABOR HEALTH AND

712
00:31:21,720 --> 00:31:24,320
HUMAN SERVICES EDUCATION AND

713
00:31:24,320 --> 00:31:29,040
RELATED AGENCIES FROM 1995

714
00:31:29,040 --> 00:31:33,240
THROUGH 2000 AND IN THAT ROLE,

715
00:31:33,240 --> 00:31:35,480
HE STRESSED ACHIEVING MEDICAL

716
00:31:35,480 --> 00:31:37,600
ADVANCES TO IDENTIFY, TREAT AND

717
00:31:37,600 --> 00:31:39,240
CONQUER DISEASE REQUIRES SUN

718
00:31:39,240 --> 00:31:42,440
PAINT SUPPORT FOR BIOMEDICAL

719
00:31:42,440 --> 00:31:45,080
RESEARCH AND NOTABLY, AS CHAIR,

720
00:31:45,080 --> 00:31:47,480
OF THE HOUSE LABOR HHS

721
00:31:47,480 --> 00:31:50,560
APPROPRIATIONS SUBCOMMITTEE

722
00:31:50,560 --> 00:31:52,800
CONGRESSMAN PORTER LED A

723
00:31:52,800 --> 00:31:54,600
SUCCESSFUL PUSH TO DOUBLE THE

724
00:31:54,600 --> 00:31:56,720
ANNUAL NIH BUDGET.

725
00:31:56,720 --> 00:32:00,440
YOU MAY BE AWARE THAT THE PORTER

726
00:32:00,440 --> 00:32:02,360
NEUROSCIENCE RESEARCH CENTER ON

727
00:32:02,360 --> 00:32:04,760
THE NIH CAMPUS IN BETHESDA IS

728
00:32:04,760 --> 00:32:09,520
NAMED IN HIS HONOR IN

729
00:32:09,520 --> 00:32:12,080
RECOGNITION OF HIS SUPPORT OF

730
00:32:12,080 --> 00:32:13,880
NIH AND ITS MISSION AND WE ARE

731
00:32:13,880 --> 00:32:16,120
GRATEFUL FOR CONGRESSMAN

732
00:32:16,120 --> 00:32:18,800
PORTER'S STRONG AND SUSTAINED

733
00:32:18,800 --> 00:32:21,160
SUPPORT FOR NIH AND HIS BELIEF

734
00:32:21,160 --> 00:32:25,040
IN THE TRANSFORMATIVE POWER OF

735
00:32:25,040 --> 00:32:26,240
MEDICAL RESEARCH.

736
00:32:26,240 --> 00:32:29,000
IT WAS MY IMMENSE HONOR TO WORK

737
00:32:29,000 --> 00:32:37,120
WITH CONGRESSMAN PORTER HE IS

738
00:32:37,120 --> 00:32:38,680
GREATLY MISSED BY THE NIH

739
00:32:38,680 --> 00:32:38,960
COMMUNITY.

740
00:32:38,960 --> 00:32:41,760
I WILL DEDICATE THE REMAINDER OF

741
00:32:41,760 --> 00:32:43,280
THIS SESSION TO A DISCUSSION

742
00:32:43,280 --> 00:32:44,520
YOU'VE ISSUES THAT HAVE ARISEN

743
00:32:44,520 --> 00:32:47,000
AND EVENTS THAT HAVE OCCURRED

744
00:32:47,000 --> 00:32:48,960
AND FOLLOW UPS OF MATTERS WE

745
00:32:48,960 --> 00:32:55,320
HAVE PREVIOUSLY DISCUSSED.

746
00:32:55,320 --> 00:32:57,000
FIRST, AN HIV/AIDS UPDATE.

747
00:32:57,000 --> 00:32:59,760
THIS SUMMER, WAS THE 21s

748
00:32:59,760 --> 00:33:01,720
21st INTERNATIONAL AIDS

749
00:33:01,720 --> 00:33:03,840
CONFERENCE IN MONTREAL WHICH WAS

750
00:33:03,840 --> 00:33:07,600
A BOTH I AM PRESENT AND VIRTUAL

751
00:33:07,600 --> 00:33:07,840
MEETING.

752
00:33:07,840 --> 00:33:09,320
HENCE A HYBRID.

753
00:33:09,320 --> 00:33:13,360
THE THEME WAS TO REENGAGE AND

754
00:33:13,360 --> 00:33:15,280
FOLLOW THE SCIENCE.

755
00:33:15,280 --> 00:33:17,520
THERE WERE MANY NEW AND

756
00:33:17,520 --> 00:33:24,440
INTERESTING ISSUES THAT CAME UP,

757
00:33:24,440 --> 00:33:26,680
OUR OWN VRC PROGRAM, NEW

758
00:33:26,680 --> 00:33:28,920
INSIGHTS INTO IDENTIFYING HIV

759
00:33:28,920 --> 00:33:32,000
CELLS AND USING THEM AS

760
00:33:32,000 --> 00:33:35,760
POTENTIAL CURE TARGETS.

761
00:33:35,760 --> 00:33:40,280
ANOTHER WAS AN INTERESTING

762
00:33:40,280 --> 00:33:43,480
NON-AIDS ISSUE.

763
00:33:43,480 --> 00:33:44,760
PRESENTED AT THE AIDS MEETING.

764
00:33:44,760 --> 00:33:49,960
THIS WAS SUPPORTED BY NIAID DMID

765
00:33:49,960 --> 00:33:53,800
SHOWING THAT TAKING ANTIBIOTICS

766
00:33:53,800 --> 00:33:57,720
AFTER SEX CUTS CLASSICAL STIs

767
00:33:57,720 --> 00:34:01,400
BY GONORRHEA, CHLAMYDIA AND

768
00:34:01,400 --> 00:34:05,080
SYPHILIS BY 66% IN MEN WHO HAVE

769
00:34:05,080 --> 00:34:08,280
SEX WITH MEN AND TRANSGENDER

770
00:34:08,280 --> 00:34:12,720
WOMEN, BOTH LIVING WITH HIV AS

771
00:34:12,720 --> 00:34:15,440
WELL AS THOSE ON PREP.

772
00:34:15,440 --> 00:34:17,360
AS I MENTIONED TO THE COUNCIL IN

773
00:34:17,360 --> 00:34:19,720
PREVIOUS PRESENTATIONS, WE HAVE

774
00:34:19,720 --> 00:34:28,240
A VERY EFFECTIVE HIV PREVENTION

775
00:34:28,240 --> 00:34:29,520
TOOLKIT HOWEVER WE ARE EXPECTING

776
00:34:29,520 --> 00:34:34,120
THE EFFICACY OF THAT BY NEW

777
00:34:34,120 --> 00:34:35,520
INNOVATIONS AND SUCH AS LONG

778
00:34:35,520 --> 00:34:38,120
ACTING ART FOR PREP AND NUDE RAL

779
00:34:38,120 --> 00:34:40,480
TRIESING ANTIBODIES AS PREP.

780
00:34:40,480 --> 00:34:43,160
HERE ARE SOME EXAMPLES.

781
00:34:43,160 --> 00:34:47,280
IN DECEMBER OF 2021, THE FDA

782
00:34:47,280 --> 00:34:51,080
APPROVED THE FIRST INJECTABLE

783
00:34:51,080 --> 00:34:53,880
TREATMENT FOR HIV PRE EXPOSURE

784
00:34:53,880 --> 00:35:00,240
PROFILAXIS WHICH IS INJECTABLE

785
00:35:00,240 --> 00:35:02,680
CABOTEGRAVIR EXTENDED-RELEASE

786
00:35:02,680 --> 00:35:03,840
INJECTABLE SUSPENSION.

787
00:35:03,840 --> 00:35:04,920
WHICH CAN BE GIVEN EVERY TWO

788
00:35:04,920 --> 00:35:07,160
MONTHS AND PREVENT HIV AQUA

789
00:35:07,160 --> 00:35:10,120
SITUATION AS WELL AS OR IN MANY

790
00:35:10,120 --> 00:35:18,600
CASES BETTER THAN ORAL PREP WITH

791
00:35:18,600 --> 00:35:18,920
TRAVADA.

792
00:35:18,920 --> 00:35:21,440
ANOTHER STUDY PRESENTED AT THE

793
00:35:21,440 --> 00:35:22,920
MEETING SHOWED SUSTAINED

794
00:35:22,920 --> 00:35:28,880
EFFICACY OF THIS LONG-ACTING

795
00:35:28,880 --> 00:35:32,720
CABOTEGRAVIR AS PREP AMONG

796
00:35:32,720 --> 00:35:36,280
CISGENDER WOMEN.

797
00:35:36,280 --> 00:35:41,120
THIS SLIDE SHOWS A COUPLE OF THE

798
00:35:41,120 --> 00:35:43,680
STUDIES THAT ARE DONE THROUGHOUT

799
00:35:43,680 --> 00:35:45,600
THE COUNTRY ON THE PROMISE OF

800
00:35:45,600 --> 00:35:49,400
USING INTERMITTENT INFUSIONS 6

801
00:35:49,400 --> 00:35:52,720
OF COMBINATIONS OF BROADLY

802
00:35:52,720 --> 00:35:55,040
NEUTRALIZING ANTIBODIES TO

803
00:35:55,040 --> 00:35:59,680
REPLACE THE NEED FOR DAILY

804
00:35:59,680 --> 00:36:08,800
ANTIRETROVIRAL THERAPY GIVEN

805
00:36:08,800 --> 00:36:10,160
ORALLY.

806
00:36:10,160 --> 00:36:13,800
WHAT IS PLOTTED IS THE

807
00:36:13,800 --> 00:36:17,280
SUPPRESSION OF PLAS MOW VIRINIA

808
00:36:17,280 --> 00:36:21,320
AFTER ANY VIRAL ORAL THERAPY WAS

809
00:36:21,320 --> 00:36:26,440
DISCONTINUED, AS AN ANALYTICAL

810
00:36:26,440 --> 00:36:27,160
TREATMENT INTERRUPTION.

811
00:36:27,160 --> 00:36:30,480
THE BROADLY NEUTRALIZING

812
00:36:30,480 --> 00:36:32,600
ANTIBODY IN BLUE DIVERGES

813
00:36:32,600 --> 00:36:36,040
GREATLY FROM THE PLACEBO IN RED

814
00:36:36,040 --> 00:36:38,080
AND AGAIN, THESE STUDIES WILL BE

815
00:36:38,080 --> 00:36:41,720
CONTINUED TO BE PURSUED FOR THE

816
00:36:41,720 --> 00:36:44,200
POSSIBILITY OF INTERMITTENTLY, A

817
00:36:44,200 --> 00:36:48,360
FEW TIMES A YEAR, HAVING PASSIVE

818
00:36:48,360 --> 00:36:50,600
TRANSFER OF ANTIBODY REPLACE THE

819
00:36:50,600 --> 00:36:53,680
NEED FOR DAILY A.R.T.

820
00:36:53,680 --> 00:36:56,520
MOVING ON TO MONKEYPOX UPDATE,

821
00:36:56,520 --> 00:37:01,360
IN AUGUST OF THIS YEAR, JUST

822
00:37:01,360 --> 00:37:02,640
LAST MONTH, CLIFF LINE AND I

823
00:37:02,640 --> 00:37:04,760
WROTE AN EDITORIAL IN THE NEW

824
00:37:04,760 --> 00:37:07,880
ENGLAND JOURNAL OF MEDICINE

825
00:37:07,880 --> 00:37:13,120
ENTITLED "MONKEYPOX PASS PAST AS

826
00:37:13,120 --> 00:37:15,320
PROLONG" AND WE SHOWED THE

827
00:37:15,320 --> 00:37:16,240
SIMILARITIES AS WELL AS

828
00:37:16,240 --> 00:37:20,160
DIFFERENCES BETWEEN THE VERY

829
00:37:20,160 --> 00:37:23,400
EARLY YEARS OF HIV AND WHAT

830
00:37:23,400 --> 00:37:24,720
WE'RE EXPERIENCING WITH THE

831
00:37:24,720 --> 00:37:28,320
EVOLUTION OF THE MONKEYPOX

832
00:37:28,320 --> 00:37:29,160
OUTBREAK.

833
00:37:29,160 --> 00:37:31,720
WHICH IS NOW, AS YOU KNOW,

834
00:37:31,720 --> 00:37:33,960
WORLDWIDE, WITH MORE THAN 55,000

835
00:37:33,960 --> 00:37:37,800
CONFIRMED CASES IN 100 COUNTRIES

836
00:37:37,800 --> 00:37:42,520
AND NOW AS OF YESTERDAY, MORE

837
00:37:42,520 --> 00:37:44,080
THAN 21,000 CASES IN THE UNITED

838
00:37:44,080 --> 00:37:47,720
STATES WHICH AS YOU SEE, LEADS

839
00:37:47,720 --> 00:37:50,000
THE COUNTRIES THROUGHOUT WORLD

840
00:37:50,000 --> 00:37:57,760
IN NUMBER OF CASES.

841
00:37:57,760 --> 00:37:59,360
MONKEYPOX COUNTERMEASURES ARE

842
00:37:59,360 --> 00:38:00,760
AVAILABLE AS A RESULT OF WORK

843
00:38:00,760 --> 00:38:02,720
DONE DECADES AGO IN PREPARATION

844
00:38:02,720 --> 00:38:11,400
FOR A SMALLPOX BIO TERROR

845
00:38:11,400 --> 00:38:14,080
ATTACK.

846
00:38:14,080 --> 00:38:20,760
AND THEY INCLUDE TPOXX, VISITDE

847
00:38:20,760 --> 00:38:26,480
AND BRYNCIDOFOVIR AND WE HAVE

848
00:38:26,480 --> 00:38:29,680
JYNNEOA AS WELL AS THE ORIGINAL

849
00:38:29,680 --> 00:38:34,120
ACAM2000 WHICH IS A LIVE

850
00:38:34,120 --> 00:38:36,520
VACCINIA VIRUS VACCINE.

851
00:38:36,520 --> 00:38:40,200
THE FDA, LAST MONTH, AUTHORIZED

852
00:38:40,200 --> 00:38:46,560
THE EMERGENCY USE MAINLY IN EUA

853
00:38:46,560 --> 00:38:51,120
FOR JYNNEOA GIVEN AS AN INTRA

854
00:38:51,120 --> 00:38:52,080
DETERMINAL VACCINATION FOR

855
00:38:52,080 --> 00:38:54,320
PEOPLE 18 YEARS OF AGE AND OLDER

856
00:38:54,320 --> 00:39:04,960
AT A HIGH-RISK OF INFECTION.

857
00:39:04,960 --> 00:39:07,600
BUT THE EUA ALLOWED FOR THE

858
00:39:07,600 --> 00:39:09,280
INTRA DETERMINAL WHICH ACTUALLY

859
00:39:09,280 --> 00:39:13,720
CAN BE GIVEN AT 1/5 OF THE DOSE

860
00:39:13,720 --> 00:39:18,160
WITH COMPARABLE INDUCTION OF

861
00:39:18,160 --> 00:39:21,040
IMMUNE RESPONSE.

862
00:39:21,040 --> 00:39:22,280
THERE ARE CLINICAL TRIALS

863
00:39:22,280 --> 00:39:23,560
LAUNCHED OR PENDING ON

864
00:39:23,560 --> 00:39:24,040
MONKEYPOX.

865
00:39:24,040 --> 00:39:26,920
VERY BRIEFLY, ON SEPTEMBER THE

866
00:39:26,920 --> 00:39:28,640
EIGHTH, THERE WAS AN ALTERNATIVE

867
00:39:28,640 --> 00:39:31,280
STRATEGY FOR ADMINISTERING INTRA

868
00:39:31,280 --> 00:39:37,160
DETERMINAL DOSES OF JYNNEOS THE

869
00:39:37,160 --> 00:39:39,280
INTRA DETERMINAL I MENTIONED.

870
00:39:39,280 --> 00:39:41,280
ON THE NINTH OF SEPTEMBER, IT

871
00:39:41,280 --> 00:39:44,960
WAS A CLINICAL TRIAL OF TPOX IN

872
00:39:44,960 --> 00:39:48,480
THE UNITED STATES AS OUT PATIENT

873
00:39:48,480 --> 00:39:49,680
TREATMENT FOR PEOPLE WITH

874
00:39:49,680 --> 00:39:54,800
MONKEYPOX AND WHAT'S PENDING

875
00:39:54,800 --> 00:39:56,280
NOW, AND WILL START THIS MONTH

876
00:39:56,280 --> 00:40:01,640
IS A TPOX STUDY IN THE

877
00:40:01,640 --> 00:40:04,600
DEMOCRATIC REPUBLIC OF THE CONGO

878
00:40:04,600 --> 00:40:09,400
A STUDY LED BY CLIFF LANE.

879
00:40:09,400 --> 00:40:12,400
LET'S MOVE ON TO COVID UPDATES.

880
00:40:12,400 --> 00:40:13,800
THERE HAVE BEEN RECENT PAPERS

881
00:40:13,800 --> 00:40:16,640
NOW THAT STARTED OFF AS PRE

882
00:40:16,640 --> 00:40:18,960
PRINTS THAT ARE NOW BEEN

883
00:40:18,960 --> 00:40:21,080
PUBLISHED IN CELL AND SCIENCE

884
00:40:21,080 --> 00:40:24,880
HIGHLY PEER-REVIEWED SHOWING

885
00:40:24,880 --> 00:40:28,680
RATHER STRONG EVIDENCE FOR THE

886
00:40:28,680 --> 00:40:29,760
NATURAL OCCURRENCE AND EVOLUTION

887
00:40:29,760 --> 00:40:35,920
OF THE COVID-19 OUTBREAK FROM

888
00:40:35,920 --> 00:40:38,240
THE WUHAN MARKET IN CENTRAL

889
00:40:38,240 --> 00:40:40,960
CHINA AND THE DATA FROM HIGHLY

890
00:40:40,960 --> 00:40:45,320
QUALIFIED VIROLOGIST HAVE

891
00:40:45,320 --> 00:40:55,800
ANALYZED THE IN A STRONG WAY

892
00:40:58,120 --> 00:40:59,480
THIS WAS A NATURAL OCCURRENCE

893
00:40:59,480 --> 00:41:02,080
JUMPING FROM ANIMALS BROUGHT TO

894
00:41:02,080 --> 00:41:04,800
THE WUHAN MARKET.

895
00:41:04,800 --> 00:41:08,240
LET'S TAKE A LOOK AT THE EPI.

896
00:41:08,240 --> 00:41:10,280
CURRENTLY, THERE ARE OVER

897
00:41:10,280 --> 00:41:11,960
600 MILLION REPORTED CASES AND

898
00:41:11,960 --> 00:41:15,280
SIX AND A HALF MILLION DEATHS

899
00:41:15,280 --> 00:41:16,720
GLOBALLY AND OTHERS I MENTIONED

900
00:41:16,720 --> 00:41:18,840
LAST TIME THE UNITED STATES IS

901
00:41:18,840 --> 00:41:21,520
DOING POORLY ON THIS AND ALMOST

902
00:41:21,520 --> 00:41:26,040
100 MILLION REPORTED CASES AND

903
00:41:26,040 --> 00:41:26,720
NOW OVER 1 MILLION DEATHS OVER

904
00:41:26,720 --> 00:41:30,720
THE TWO AND A HALF YEARS OF THIS

905
00:41:30,720 --> 00:41:31,680
OUTBREAK.

906
00:41:31,680 --> 00:41:33,920
AS SHOWN HERE, WE ARE DOMINATED

907
00:41:33,920 --> 00:41:36,520
BY A BA5 ISOLATE SHOWN IN THE

908
00:41:36,520 --> 00:41:37,960
PURPLE ON THE RIGHT-HAND SIDE

909
00:41:37,960 --> 00:41:48,240
WHICH GRADUALLY.

910
00:41:58,840 --> 00:42:01,280
>> IF YOU LOOK AT THE
DAILY

911
00:42:01,280 --> 00:42:03,760
CONFIRMED CASES IN THE UNITED

912
00:42:03,760 --> 00:42:07,880
STATES, AND COMPARE LAST WINTER

913
00:42:07,880 --> 00:42:10,800
IN JANUARY WITH TODAY, EVEN

914
00:42:10,800 --> 00:42:12,720
THOUGH THAT NUMBER IS

915
00:42:12,720 --> 00:42:13,640
UNACCEPTABLY HIGH AT A WEEKLY

916
00:42:13,640 --> 00:42:19,160
AVERAGE OF 75,000, IT IS A BIG

917
00:42:19,160 --> 00:42:20,360
DIFFERENCE FROM WHAT WE SAW IN

918
00:42:20,360 --> 00:42:23,560
JANUARY OF 800,000 A DAY.

919
00:42:23,560 --> 00:42:25,560
SAME WITH THE DEATHS.

920
00:42:25,560 --> 00:42:28,040
IN JANUARY WE WERE AVERAGING

921
00:42:28,040 --> 00:42:30,400
OVER 6,000 DEATHS PER DAY AND WE

922
00:42:30,400 --> 00:42:34,640
ARE NOW ABOUT 400.

923
00:42:34,640 --> 00:42:37,200
AGAIN, 400 IS AN UNACCEPTABLY

924
00:42:37,200 --> 00:42:38,600
HIGH LEVEL BUT JUST TO SHOW YOU

925
00:42:38,600 --> 00:42:42,120
THE DIFFERENCE BETWEEN THE STAGE

926
00:42:42,120 --> 00:42:46,120
IN JANUARY, AND WHERE WE ARE

927
00:42:46,120 --> 00:42:46,320
TODAY.

928
00:42:46,320 --> 00:42:48,240
AS I MENTIONED MANY TIMES, WE

929
00:42:48,240 --> 00:42:54,680
HAVE A THERAPEUTIC TOOLKIT FOR

930
00:42:54,680 --> 00:42:58,360
NON-HOSPITALIZED PATIENTS WITH

931
00:42:58,360 --> 00:43:00,960
PAXLOVID SHOWING CLEAR-CUT,

932
00:43:00,960 --> 00:43:02,160
HIGHLY EFFECTIVE AND KEEPING

933
00:43:02,160 --> 00:43:04,160
PEOPLE OUT OF THE HOSPITALS AS

934
00:43:04,160 --> 00:43:10,160
WELL AS OTHERS INCLUDING

935
00:43:10,160 --> 00:43:15,640
RECOMMENDDESIVIR AND MOLNUPIRAVI

936
00:43:15,640 --> 00:43:22,400
R & B TELOVIMAB AND ALSO A

937
00:43:22,400 --> 00:43:26,400
PROFILAXIS REDUCED THE RISK BY

938
00:43:26,400 --> 00:43:30,200
80% OF DEVELOPING SYMPTOMATIC

939
00:43:30,200 --> 00:43:32,440
COVID COMPARED TO A PLACEBO.

940
00:43:32,440 --> 00:43:34,360
WE KNOW OF THE VACCINES WITH THE

941
00:43:34,360 --> 00:43:37,040
MODERNA AND THE BIOEN TECH

942
00:43:37,040 --> 00:43:38,760
PFIZER AND mRNA AS WELL AS THE

943
00:43:38,760 --> 00:43:45,200
J AND J AND NOW OTHERS INCLUDING

944
00:43:45,200 --> 00:43:47,000
THOSE AVAILABLE THROUGH EUA OR

945
00:43:47,000 --> 00:43:52,480
AS A BLA.

946
00:43:52,480 --> 00:43:55,080
RIGHT NOW WE'RE FOCUSING ON

947
00:43:55,080 --> 00:43:57,200
UPDATING THE VACCINES FOR THE

948
00:43:57,200 --> 00:44:00,600
ENTIRE COUNTRY AND NOW, THERE

949
00:44:00,600 --> 00:44:02,560
WAS A PRELIMINARY RESULT

950
00:44:02,560 --> 00:44:06,360
REPORTED IN A PRE PRINT THAT

951
00:44:06,360 --> 00:44:12,360
HIGHER OMICRON BA1 TITERS WERE

952
00:44:12,360 --> 00:44:15,400
OBSERVED COMPARED TO PROTOTYPE

953
00:44:15,400 --> 00:44:18,000
VACCINES AND THE TITERS AGAINST

954
00:44:18,000 --> 00:44:21,680
THE OMICRON BA45 WERE LOWER

955
00:44:21,680 --> 00:44:23,800
AGAINST BA1 ON ALL CANDIDATE

956
00:44:23,800 --> 00:44:24,080
VACCINES.

957
00:44:24,080 --> 00:44:26,640
BUT BASED ON THE TOTALITY OF

958
00:44:26,640 --> 00:44:28,200
EVIDENCE, AND THE EXPERIENCE OF

959
00:44:28,200 --> 00:44:34,360
THE BA1 OMICRON BIVALENT, THE

960
00:44:34,360 --> 00:44:36,720
CDC RECOMMENDED THE FIRST

961
00:44:36,720 --> 00:44:38,000
UPDATED COVID-19 BOOSTER WHICH

962
00:44:38,000 --> 00:44:42,080
IS A BIVALENT BA4-5 VACCINE AND

963
00:44:42,080 --> 00:44:44,600
FOR INDIVIDUALS OLDER THAN 12 OR

964
00:44:44,600 --> 00:44:48,280
OLDER FOR THE PFIZER mRNA AND

965
00:44:48,280 --> 00:44:52,080
INDIVIDUALS 18 OR OLDER WITH THE

966
00:44:52,080 --> 00:44:53,280
MODERNA mRNA.

967
00:44:53,280 --> 00:44:56,000
AND IN THE COMING WEEKS, THE CDC

968
00:44:56,000 --> 00:44:57,720
WILL BE EXPECTED TO RECOMMEND

969
00:44:57,720 --> 00:45:00,880
THAT UPDATED BOOST FOR THE OTHER

970
00:45:00,880 --> 00:45:02,680
PEDIATRIC GROUPS NAMELY THOSE

971
00:45:02,680 --> 00:45:04,760
YOUNGER THAN 12.

972
00:45:04,760 --> 00:45:07,240
LET ME QUICKLY MOVE ON TO NOW A

973
00:45:07,240 --> 00:45:10,320
REAL NEED, THE NEXT GENERATION

974
00:45:10,320 --> 00:45:11,760
CORONAVIRUS VACCINES.

975
00:45:11,760 --> 00:45:22,240
EITHER THE PAN-AND WE WROTE A

976
00:45:23,960 --> 00:45:26,160
PERSPECTIVE CALLING THE

977
00:45:26,160 --> 00:45:27,080
UNIVERSAL CORONAVIRUS VACCINES

978
00:45:27,080 --> 00:45:30,800
TRULY AN URGENT NEED GIVING THE

979
00:45:30,800 --> 00:45:32,840
EXPERIENCE WE'VE HAD WITH

980
00:45:32,840 --> 00:45:33,520
MULTIPLE VARIANTS.

981
00:45:33,520 --> 00:45:36,800
THERE'S A LOT OF REALLY GOOD

982
00:45:36,800 --> 00:45:39,920
WORK ALREADY GOING ON IN THE

983
00:45:39,920 --> 00:45:41,800
SPACE OF PAN CORONAVIRUS

984
00:45:41,800 --> 00:45:45,080
VACCINES PRE CLINICAL AND EARLY

985
00:45:45,080 --> 00:45:46,000
CLINICAL WORK.

986
00:45:46,000 --> 00:45:48,400
IN FACT, THERE'S A PAPER THAT

987
00:45:48,400 --> 00:45:51,040
JUST CAME OUT IN SCIENCE ABOUT A

988
00:45:51,040 --> 00:45:54,120
MONTH AGO, USING NANO PARTICLES

989
00:45:54,120 --> 00:45:56,960
WHICH PROTECT AGAINST CHALLENGED

990
00:45:56,960 --> 00:46:00,840
BY DIVERSE VIRUSES IN ANIMAL

991
00:46:00,840 --> 00:46:02,440
INFORMEDEL AND THE NIAID HAS

992
00:46:02,440 --> 00:46:05,720
MADE SIX RECENT AWARDS TOTALING

993
00:46:05,720 --> 00:46:06,920
ALMOST $60 MILLION FOR RESEARCH

994
00:46:06,920 --> 00:46:10,960
ON THESE BROADLY-PROTECTIVE

995
00:46:10,960 --> 00:46:12,360
CORONAVIRUS VACCINES WITH

996
00:46:12,360 --> 00:46:14,280
THREE-YEAR GRANTS IN THE

997
00:46:14,280 --> 00:46:16,400
INSTITUTION'S SHOWN HERE.

998
00:46:16,400 --> 00:46:19,480
ALSO, MUCOSAL VACCINES, WE KNOW,

999
00:46:19,480 --> 00:46:23,000
ARE EXTREMELY IMPORTANT FOR OUR

1000
00:46:23,000 --> 00:46:25,640
FUTURE AGAINST PROTECTING

1001
00:46:25,640 --> 00:46:29,200
INFECTION AND TRANSMISSION.

1002
00:46:29,200 --> 00:46:31,680
THIS WAS NICELY REVIEWED IN AN

1003
00:46:31,680 --> 00:46:34,880
ARTICLE LAST MONTH BY ERIC TOPOL

1004
00:46:34,880 --> 00:46:37,520
ABOUT WHAT WE NEED TO DO WITH

1005
00:46:37,520 --> 00:46:40,240
REGARD TO NASAL VACCINES TO

1006
00:46:40,240 --> 00:46:43,600
COUNTER FUTURE COVID-19 AS WELL

1007
00:46:43,600 --> 00:46:45,960
AS PRESENT AS ILLUSTRATED DEM

1008
00:46:45,960 --> 00:46:47,640
ATTICLY THESE TYPE OF VACCINES

1009
00:46:47,640 --> 00:46:49,520
WILL GIVE FASTER I AM AN TEE

1010
00:46:49,520 --> 00:46:53,520
RECALL AFTER EXPOSURE AND ARE

1011
00:46:53,520 --> 00:46:55,000
GEARED AT INFECTION AND

1012
00:46:55,000 --> 00:46:57,600
TRANSMISSION BLOCKING.

1013
00:46:57,600 --> 00:46:59,640
AND ALSO THE ADVANTAGE OF BEING

1014
00:46:59,640 --> 00:47:00,360
NEEDLE FREE.

1015
00:47:00,360 --> 00:47:04,120
ONE EXAMPLE OF THIS IS AN

1016
00:47:04,120 --> 00:47:06,240
INACTIVATED WHOLE VIRUS

1017
00:47:06,240 --> 00:47:08,840
CONSISTING OF SARS-CoV-2 FROM

1018
00:47:08,840 --> 00:47:10,920
DIFFERENT STRAINS GIVEN BY AN

1019
00:47:10,920 --> 00:47:14,720
INTER NASAL MIST IN A STUDY BY

1020
00:47:14,720 --> 00:47:18,840
JEFF TAUBENBERGE SO THERE ARE

1021
00:47:18,840 --> 00:47:20,840
GOOD PEOPLE EXTRAMURALLY WORKING

1022
00:47:20,840 --> 00:47:22,880
ON THIS AND VERY QUICKLY LET ME

1023
00:47:22,880 --> 00:47:24,800
CLOSE WITH A COUPLE OF OTHER

1024
00:47:24,800 --> 00:47:25,000
UPDATES.

1025
00:47:25,000 --> 00:47:26,840
VERY EXCITING WORK COMING FROM

1026
00:47:26,840 --> 00:47:30,680
THE VRC WITH BOB CEDAR AND HIS

1027
00:47:30,680 --> 00:47:33,280
COLLEAGUES IN A SINGLE INJECTION

1028
00:47:33,280 --> 00:47:37,320
OF THE ANTIBODY L9LS WAS SAFE

1029
00:47:37,320 --> 00:47:39,120
AND HIGHLY PROTECTED IN THE

1030
00:47:39,120 --> 00:47:41,360
UNITED STATES ADULTS EXPOSED TO

1031
00:47:41,360 --> 00:47:42,760
MALARIA PARASITES AND WE'RE

1032
00:47:42,760 --> 00:47:45,320
GOING TO DO A LARGER TRIAL IN

1033
00:47:45,320 --> 00:47:48,040
AFRICAN INFANTS AND CHILDREN.

1034
00:47:48,040 --> 00:47:50,720
WE CONTINUE WITH THE WORK

1035
00:47:50,720 --> 00:47:53,360
TOWARDS OUR PROTOTYPE PATHOGENS

1036
00:47:53,360 --> 00:47:56,160
APPROACH FOR VACCINES AND MONO

1037
00:47:56,160 --> 00:47:58,560
CRON ALAN TEE BODY WHICH SAY

1038
00:47:58,560 --> 00:48:01,800
CRITICAL CAM PHONE ANT OF THE

1039
00:48:01,800 --> 00:48:03,080
BROADER NIAID PLAN FOR PANDEMIC

1040
00:48:03,080 --> 00:48:03,400
PREPAREDNESS.

1041
00:48:03,400 --> 00:48:06,240
OUR STAFF AND I OUTLINED THIS IN

1042
00:48:06,240 --> 00:48:08,040
A RECENT COMMENTARY IN THE

1043
00:48:08,040 --> 00:48:10,520
JOURNAL OF INFECTIOUS DISEASES.

1044
00:48:10,520 --> 00:48:13,440
THESE ARE THE TOP PRIORITIES OF

1045
00:48:13,440 --> 00:48:16,040
THE VARIOUS FAMILIES AND WE'RE

1046
00:48:16,040 --> 00:48:17,920
ALREADY WORKING ON SEVERAL OF

1047
00:48:17,920 --> 00:48:19,440
THESE, FOR EXAMPLE, WE LAUNCHED

1048
00:48:19,440 --> 00:48:23,120
THE CLINICAL TRIAL OF mRNA NIP

1049
00:48:23,120 --> 00:48:24,840
OWE VIRUS VACCINES AS PHASE 1 AT

1050
00:48:24,840 --> 00:48:28,800
THE NIH CLINICAL CENTER AND A

1051
00:48:28,800 --> 00:48:35,080
PREVAIL STUDY DONE IN LI LIBERIS

1052
00:48:35,080 --> 00:48:37,080
A VACCINE AGAIN A VERY IMPORTANT

1053
00:48:37,080 --> 00:48:39,520
DISEASE IN THAT PART OF THE

1054
00:48:39,520 --> 00:48:40,000
WORLD.

1055
00:48:40,000 --> 00:48:42,720
AND ALSO THERE'S ENCOURAGING

1056
00:48:42,720 --> 00:48:45,320
PROGRESS ON RSV VACCINES WORK

1057
00:48:45,320 --> 00:48:48,040
THAT ORIGINATED FROM THE

1058
00:48:48,040 --> 00:48:49,800
FUNDAMENTAL BASIC RESEARCH DONE

1059
00:48:49,800 --> 00:48:52,680
BY BONNIE GRAHAM IN THE VRC

1060
00:48:52,680 --> 00:48:53,360
YEARS AGO.

1061
00:48:53,360 --> 00:48:55,720
AND LET ME CLOSE ON THIS LAST

1062
00:48:55,720 --> 00:48:57,120
SLIDE, SO THAT WE DON'T FORGET

1063
00:48:57,120 --> 00:48:59,480
THE IMPORTANCE OF THE WORK THAT

1064
00:48:59,480 --> 00:49:01,960
WE'RE DOING TO DEVELOP A CURE

1065
00:49:01,960 --> 00:49:06,120
FOR HEPATITIS B AS SHOWN IN OUR

1066
00:49:06,120 --> 00:49:08,240
UPDATE THAT WAS PUBLISHED BY THE

1067
00:49:08,240 --> 00:49:12,480
NIH HEPATITIS B STRATEGIC PLAN

1068
00:49:12,480 --> 00:49:20,080
WORKING GROUP IN JULY 20622.

1069
00:49:20,080 --> 00:49:20,680
 OF 2022.

1070
00:49:20,680 --> 00:49:22,440
SO I'LL STOP THERE AND BE HAPPY

1071
00:49:22,440 --> 00:49:23,320
TO ANSWER ANY QUESTIONS.

1072
00:49:23,320 --> 00:49:29,320
THANK YOU.

1073
00:49:29,320 --> 00:49:31,720
>> OK, WELL, IF THERE ARE
NO

1074
00:49:31,720 --> 00:49:35,920
QUESTIONS, I CAN SEE, WE'LL HAVE

1075
00:49:35,920 --> 00:49:38,640
TIME AT THE END AND I'LL BE ABLE

1076
00:49:38,640 --> 00:49:42,280
TO GIVE THE OPPORTUNITY AFTER WE

1077
00:49:42,280 --> 00:49:44,600
GET THE LAST PRESENTATION FROM

1078
00:49:44,600 --> 00:49:47,520
Dr. HOLLAND.

1079
00:49:47,520 --> 00:49:49,640
I DID NOT MENTION IN THE

1080
00:49:49,640 --> 00:49:51,320
INTERESTING SOMETHING THAT I

1081
00:49:51,320 --> 00:49:54,280
SHOULD HAVE AND THAT IS THAT

1082
00:49:54,280 --> 00:49:55,800
THERE ARE SEVERAL MEMBERS WHOSE

1083
00:49:55,800 --> 00:50:00,080
TERMS ARE EXPIRING ON

1084
00:50:00,080 --> 00:50:00,400
OCTOBER 2022.

1085
00:50:00,400 --> 00:50:02,920
AND I JUST WANT TO MENTION THEM

1086
00:50:02,920 --> 00:50:05,120
AND THANK THEM FOR THEIR SERVICE

1087
00:50:05,120 --> 00:50:10,360
TO US AND THAT IS Dr. ARGUILE,

1088
00:50:10,360 --> 00:50:18,160
Mr. IBOW, Dr. GUPTA, Dr.

1089
00:50:18,160 --> 00:50:20,040
RANDOLPH, AND Dr. RAY, SO

1090
00:50:20,040 --> 00:50:22,280
THANK YOU SO MUCH FOR YOUR

1091
00:50:22,280 --> 00:50:23,520
SERVICE TO US.

1092
00:50:23,520 --> 00:50:26,000
AND BEFORE I INTRODUCE OUR NEXT

1093
00:50:26,000 --> 00:50:33,080
SPEAKER, I JUST WANTED TO

1094
00:50:33,080 --> 00:50:35,080
ACKNOWLEDGE AFTER 38 YEARS

1095
00:50:35,080 --> 00:50:36,320
PRESIDING OVER THESE COUNCIL

1096
00:50:36,320 --> 00:50:37,720
MEETINGS, THIS WILL BE THE LAST

1097
00:50:37,720 --> 00:50:40,120
COUNCIL MEETING I WILL ADDRESS

1098
00:50:40,120 --> 00:50:41,160
AS NIAID DIRECTOR AND I JUST

1099
00:50:41,160 --> 00:50:43,000
WANT TO MENTION VERY SINCERELY

1100
00:50:43,000 --> 00:50:47,360
THIS HAS BEEN AN ENORMOUS

1101
00:50:47,360 --> 00:50:48,560
PLEASURE AND PRIVILEGE OF MY JOB

1102
00:50:48,560 --> 00:50:52,600
TO HAVE WORKED WITH THE MANY

1103
00:50:52,600 --> 00:50:55,560
EXTRAORDINARY AND TALENTED

1104
00:50:55,560 --> 00:50:56,680
INDIVIDUALS WHO SERVED ON OUR

1105
00:50:56,680 --> 00:50:57,520
COUNCIL, OVER THE YEARS.

1106
00:50:57,520 --> 00:51:01,960
WE HAVE A TRULY OUTSTANDING

1107
00:51:01,960 --> 00:51:04,360
INSTITUTE STRENGTHENED BY OUR

1108
00:51:04,360 --> 00:51:07,320
INTERACTIONS WITH OUR COUNCIL.

1109
00:51:07,320 --> 00:51:09,080
I'M CONFIDENT THE INSTITUTE WILL

1110
00:51:09,080 --> 00:51:12,120
BE IN KALE ABLE HANDS AFTER I

1111
00:51:12,120 --> 00:51:13,560
LEAVE AND I WANT TO THANK THOSE

1112
00:51:13,560 --> 00:51:17,400
OF YOU HERE TODAY FOR YOUR

1113
00:51:17,400 --> 00:51:18,960
SERVICE TO OUR INSTITUTE AS WELL

1114
00:51:18,960 --> 00:51:21,200
AS PAST COUNCIL MEMBERS THAT

1115
00:51:21,200 --> 00:51:24,400
HAVE SERVED US SO WELL OVER THE

1116
00:51:24,400 --> 00:51:24,720
YEARS.

1117
00:51:24,720 --> 00:51:26,280
COUNCIL MEMBERS ARE CRITICAL

1118
00:51:26,280 --> 00:51:31,600
ADVISERS WHO BRING TO THE TABLE

1119
00:51:31,600 --> 00:51:33,120
OUTSIDE PERSPECTIVES AND IDEAS

1120
00:51:33,120 --> 00:51:35,240
THAT HELP AND SHAPE AND ADVANCE

1121
00:51:35,240 --> 00:51:39,360
OUR MISSION SO THANK YOU SO MUCH

1122
00:51:39,360 --> 00:51:40,200
FOR THAT.

1123
00:51:40,200 --> 00:51:42,640
NOW I WOULD LIKE TO INTRODUCE

1124
00:51:42,640 --> 00:51:45,560
Dr. STEVEN HOLLAND THE

1125
00:51:45,560 --> 00:51:47,320
DIRECTOR OF YOU ARE INTRAMURAL

1126
00:51:47,320 --> 00:51:48,240
RESEARCH PROGRAM WHO WILL

1127
00:51:48,240 --> 00:51:49,760
PRESENT DURING THE NEXT PART OF

1128
00:51:49,760 --> 00:51:50,680
OUR PROGRAM.

1129
00:51:50,680 --> 00:51:51,160
STEVE, OVER TO YOU.

1130
00:51:51,160 --> 00:51:52,800
>> THANK YOU SO MUCH, TONY
AND

1131
00:51:52,800 --> 00:51:54,760
THANK YOU FOR YOUR EXTRAORDINARY

1132
00:51:54,760 --> 00:51:55,840
YEARS OF SERVICE.

1133
00:51:55,840 --> 00:51:57,720
IT HAS BEEN A REAL HONOR AND

1134
00:51:57,720 --> 00:51:59,280
PLEASURE TO SERVE UNDER WOW.

1135
00:51:59,280 --> 00:52:01,280
AND I WILL NOW JUST GIVE A VERY

1136
00:52:01,280 --> 00:52:03,960
BRIEF UPDATE ON THE INTRAMURAL

1137
00:52:03,960 --> 00:52:07,920
PROGRAM AND I'M GOING TO SHARE

1138
00:52:07,920 --> 00:52:10,280
MY SLIDES HERE BRIEFLY.

1139
00:52:10,280 --> 00:52:12,320
IS THAT IN THE RIGHT MODE?

1140
00:52:12,320 --> 00:52:13,360
>> THAT'S CORRECT.

1141
00:52:13,360 --> 00:52:14,920
>> VERY GOOD.

1142
00:52:14,920 --> 00:52:16,760
OK, SO I WILL GET RIGHT TO THE

1143
00:52:16,760 --> 00:52:17,000
POINT.

1144
00:52:17,000 --> 00:52:18,680
I'M GOING TO TALK TO YOU ABOUT

1145
00:52:18,680 --> 00:52:21,560
THE INTRAMURAL PROGRAMS AND THE

1146
00:52:21,560 --> 00:52:22,960
PRESENT, THE RECENT PAST THIS

1147
00:52:22,960 --> 00:52:25,000
LAST YEAR AND SOME VERY FEW

1148
00:52:25,000 --> 00:52:26,400
SELECT RESEARCH HIGHLIGHTS AND

1149
00:52:26,400 --> 00:52:28,400
THEN I NEED YOUR HELP AT THE

1150
00:52:28,400 --> 00:52:30,040
VERY END.

1151
00:52:30,040 --> 00:52:33,040
SO, REMEMBER, INTRAMURAL

1152
00:52:33,040 --> 00:52:35,160
RESEARCH, INSIDE THE WALLS IS

1153
00:52:35,160 --> 00:52:38,040
WHAT WE'RE TALKING ABOUT AND THE

1154
00:52:38,040 --> 00:52:39,360
CURRENCY STEMS FROM THE BOARD OF

1155
00:52:39,360 --> 00:52:40,440
SCIENTIFIC COUNCILORS REVIEW.

1156
00:52:40,440 --> 00:52:42,320
EVERY LAB, EVERY PRINCIPLE

1157
00:52:42,320 --> 00:52:43,840
INVESTIGATOR, AT LAST EVERY FOUR

1158
00:52:43,840 --> 00:52:47,360
YEARS GETS REVIEWED AND THIS IS

1159
00:52:47,360 --> 00:52:49,400
A LARGE HIGHLY PROFESSIONAL,

1160
00:52:49,400 --> 00:52:50,720
VERY ACCOMPLISHED GROUP, MANY OF

1161
00:52:50,720 --> 00:52:53,360
YOU HAVE SERVED ON THESE

1162
00:52:53,360 --> 00:52:54,760
COMMITTEES.

1163
00:52:54,760 --> 00:52:57,080
CURRENTLY, WE ONLY DO IT TWICE A

1164
00:52:57,080 --> 00:52:58,760
YEAR IN DECEMBER AND JUNE AND

1165
00:52:58,760 --> 00:53:00,080
WE'RE DOING OUR BEST TO KEEP IT

1166
00:53:00,080 --> 00:53:00,920
TO THAT LEVEL.

1167
00:53:00,920 --> 00:53:02,200
IT'S HARD, INTENSE AND IT'S A

1168
00:53:02,200 --> 00:53:03,640
LOT OF READING AND A LOT OF

1169
00:53:03,640 --> 00:53:06,080
QUESTIONING AND A LOT OF

1170
00:53:06,080 --> 00:53:08,440
LEARNING FOR EVERYBODY INVOLVED.

1171
00:53:08,440 --> 00:53:09,520
WE STRIVE TO MAKE SURE THAT ALL

1172
00:53:09,520 --> 00:53:11,920
OF OUR WORK IS AGAIN EYE INLY

1173
00:53:11,920 --> 00:53:13,440
OUT STANDING AND WE NEED YOUR

1174
00:53:13,440 --> 00:53:15,080
INPUT TO MAKE SURE THAT WE STAY

1175
00:53:15,080 --> 00:53:15,920
TO THAT MARK.

1176
00:53:15,920 --> 00:53:18,880
AND REALLY FROM THAT EVALUATION,

1177
00:53:18,880 --> 00:53:19,920
ALL THINGS FLOW.

1178
00:53:19,920 --> 00:53:24,600
THIS IS JUST A BRIEF LOOK AT THE

1179
00:53:24,600 --> 00:53:25,680
NUMBER OF PRINCIPLE

1180
00:53:25,680 --> 00:53:27,960
INVESTIGATORS IN THE INTRAMURAL

1181
00:53:27,960 --> 00:53:28,160
PROGRAM.

1182
00:53:28,160 --> 00:53:29,600
WE HAVE FLUCTUATED SOME OVER THE

1183
00:53:29,600 --> 00:53:32,000
YEARS AND WE'VE NOW GOT A GOOD

1184
00:53:32,000 --> 00:53:34,720
NUMBER ON TENURE TRACK AND WE'RE

1185
00:53:34,720 --> 00:53:37,920
LOOKING FORWARD TO MAKING THESE

1186
00:53:37,920 --> 00:53:39,440
THINGS COME TO LIFE.

1187
00:53:39,440 --> 00:53:41,960
SO, REMINDING YOU THE PROGRAM

1188
00:53:41,960 --> 00:53:43,600
HAS SEVERAL COMPONENTS.

1189
00:53:43,600 --> 00:53:45,960
THE INTRAMURAL PART HERE IN

1190
00:53:45,960 --> 00:53:47,040
BETHESDA IS SHOWN AT THE TOP OF

1191
00:53:47,040 --> 00:53:47,640
THE SLIDE.

1192
00:53:47,640 --> 00:53:50,560
OUR CAMPUS AT ROCKY MOUNTAIN IN

1193
00:53:50,560 --> 00:53:52,520
HAMILTON, MONTANA, WHERE WE DO

1194
00:53:52,520 --> 00:53:54,960
SO MUCH OF THE REALLY

1195
00:53:54,960 --> 00:53:56,680
EXTRAORDINARY VSL3 AND 4 WORK

1196
00:53:56,680 --> 00:53:59,160
AND THERE ARE MANY SITES AROUND

1197
00:53:59,160 --> 00:54:02,560
THE GLOBE THAT ARE PART OF THE

1198
00:54:02,560 --> 00:54:03,880
INTRAMURAL PROGRAM AS WELL AS

1199
00:54:03,880 --> 00:54:07,080
MANY CRITICAL EXTRAMURAL

1200
00:54:07,080 --> 00:54:07,560
COMPONENTS.

1201
00:54:07,560 --> 00:54:09,240
SO OUR PRIORITIES IN THE

1202
00:54:09,240 --> 00:54:10,280
INTRAMURAL PROGRAM ARE TO MAKE

1203
00:54:10,280 --> 00:54:12,040
SURE WE'RE DOING TRANSFORMATIVE

1204
00:54:12,040 --> 00:54:13,480
MEDICINE AND BIO MEDICAL

1205
00:54:13,480 --> 00:54:16,080
RESEARCH AND THE

1206
00:54:16,080 --> 00:54:17,000
BENCH-TO-BEDSIDE APPROACH THAT

1207
00:54:17,000 --> 00:54:18,040
TAKES FULL ADVANTAGE OF THE

1208
00:54:18,040 --> 00:54:19,280
CLINICAL CENTER WHICH IS REALLY

1209
00:54:19,280 --> 00:54:21,440
QUITE A PRIVILEGE TO HAVE AND AS

1210
00:54:21,440 --> 00:54:23,560
WELL AS OUR DOMESTIC AND

1211
00:54:23,560 --> 00:54:24,360
INTERNATIONAL SITES.

1212
00:54:24,360 --> 00:54:26,640
WE WANT TO BE RESPONDING TO

1213
00:54:26,640 --> 00:54:28,000
PUBLIC-HEALTH THREATS INCLUDING

1214
00:54:28,000 --> 00:54:31,840
DRUG RESISTANT MICROBES,

1215
00:54:31,840 --> 00:54:32,760
EMERGING VIRUSES AND THE

1216
00:54:32,760 --> 00:54:33,840
DESPERATELY NEEDED VACCINES THAT

1217
00:54:33,840 --> 00:54:35,360
HAVE BEEN SO IMPORTANT TO US.

1218
00:54:35,360 --> 00:54:37,000
WE WANT TO PARTNER TO ADVANCE

1219
00:54:37,000 --> 00:54:39,720
THESE APPROACHES AND TO DO IT

1220
00:54:39,720 --> 00:54:41,520
ACROSS BOTH INFECTIOUS AND

1221
00:54:41,520 --> 00:54:43,560
IMMUNE LOGIC DISEASES.

1222
00:54:43,560 --> 00:54:45,120
SO WHAT HAVE WE DONE IN THE LAST

1223
00:54:45,120 --> 00:54:46,080
YEAR?

1224
00:54:46,080 --> 00:54:48,320
WE'VE GOT 802 PUBLICATIONS SO

1225
00:54:48,320 --> 00:54:50,360
FAR AND THE YEAR IS NOT OVER FOR

1226
00:54:50,360 --> 00:54:50,640
US.

1227
00:54:50,640 --> 00:54:53,360
THERE HAVE BEEN MANY THINGS

1228
00:54:53,360 --> 00:54:54,480
HIGHLIGHTED BY THE NIAID BLOG

1229
00:54:54,480 --> 00:54:56,480
AND WE HAVE ABOUT 200 ACTIVE

1230
00:54:56,480 --> 00:54:57,640
CLINICAL STUDIES GOING ON

1231
00:54:57,640 --> 00:54:59,720
THROUGH THE INSTITUTE.

1232
00:54:59,720 --> 00:55:02,800
AS TONY MENTIONED, COVID FUNDING

1233
00:55:02,800 --> 00:55:04,480
HAS BEEN AN IMPORTANT PART OF

1234
00:55:04,480 --> 00:55:05,680
WHAT WE'VE BEEN WORKING WITH FOR

1235
00:55:05,680 --> 00:55:08,000
THE LAST COUPLE OF YEARS.

1236
00:55:08,000 --> 00:55:10,160
AND WITH THAT FUNDING, WE HAD

1237
00:55:10,160 --> 00:55:13,440
MORE THAN 60% OF OUR PRINCIPLE

1238
00:55:13,440 --> 00:55:16,600
INVESTIGATORS TAKE ON AND

1239
00:55:16,600 --> 00:55:18,560
DEVELOP COVID PROJECTS LEADING

1240
00:55:18,560 --> 00:55:23,000
TO NOW 451 PUBLICATIONS AND

1241
00:55:23,000 --> 00:55:26,160
80PIs AND BRANCHES WERE FUNDED

1242
00:55:26,160 --> 00:55:26,440
INITIALLY.

1243
00:55:26,440 --> 00:55:27,240
CURRENTLY THAT NUMBER HAS FALLEN

1244
00:55:27,240 --> 00:55:29,000
A LITTLE BIT AS PEOPLE HAVE

1245
00:55:29,000 --> 00:55:31,760
COMPLETED PROJECTS THAT HAVE NOW

1246
00:55:31,760 --> 00:55:36,560
MOVED ON BACK TO THEIR PRIMARY

1247
00:55:36,560 --> 00:55:36,840
INTERESTS.

1248
00:55:36,840 --> 00:55:38,360
ONE OF THE APPROACHES WE'VE

1249
00:55:38,360 --> 00:55:41,680
TAKEN TO THIS IS TO CREATE A

1250
00:55:41,680 --> 00:55:44,280
SARS-CoV-2 VIROLOGY CORE WHERE

1251
00:55:44,280 --> 00:55:46,800
WE CAN DO THE VSL3 WORK REQUIRED

1252
00:55:46,800 --> 00:55:48,440
WITH PEOPLE WHO ARE EXPERT IN IT

1253
00:55:48,440 --> 00:55:51,400
SO LABS WITH GOOD IDEAS COULD

1254
00:55:51,400 --> 00:55:54,080
COME IN AND MAKE THOSE IDEAS

1255
00:55:54,080 --> 00:55:56,600
WHOLE BUT DO IT WITH EXPERTS

1256
00:55:56,600 --> 00:55:59,280
THAT WILL HELP US TO DO IT

1257
00:55:59,280 --> 00:55:59,680
SAFELY.

1258
00:55:59,680 --> 00:56:00,720
TED PIERSON THE CHIEF OF THE

1259
00:56:00,720 --> 00:56:02,360
LABRADOR OF VIRAL DISEASES PUT

1260
00:56:02,360 --> 00:56:04,880
TOGETHER THIS OUTSTANDING GROUP

1261
00:56:04,880 --> 00:56:08,440
LED BY REID JOHNSON AND NICOLE

1262
00:56:08,440 --> 00:56:09,600
LACKMIRE AND IT'S BEEN

1263
00:56:09,600 --> 00:56:10,760
SUPPORTING RESEARCH FROM AROUND

1264
00:56:10,760 --> 00:56:12,560
THE CAMPUS FROM LABORATORIES

1265
00:56:12,560 --> 00:56:15,280
THAT DID NOT HAVE BSL3 CAPACITY.

1266
00:56:15,280 --> 00:56:16,840
IT'S BEEN VERY SUCCESSFUL AND AS

1267
00:56:16,840 --> 00:56:18,520
WE TRY TO THINK THROUGH WHAT IS

1268
00:56:18,520 --> 00:56:21,000
THE APPROACH WE WANT TO BE

1269
00:56:21,000 --> 00:56:21,920
DEVELOPING FOR PANDEMIC

1270
00:56:21,920 --> 00:56:23,480
PREPAREDNESS IN THE INTRAMURAL

1271
00:56:23,480 --> 00:56:25,040
PROGRAM, THIS IS ONE OF THE

1272
00:56:25,040 --> 00:56:27,520
THINGS THAT I THINK WILL BE A

1273
00:56:27,520 --> 00:56:28,720
PARADIGM FOR US.

1274
00:56:28,720 --> 00:56:31,640
OF COURSE, IN THE LAST FEW

1275
00:56:31,640 --> 00:56:33,520
MONTHS, MONKEYPOX HAS BEEN AN

1276
00:56:33,520 --> 00:56:35,320
IMPORTANT COMPONENT OF OUR

1277
00:56:35,320 --> 00:56:37,720
THINKING AND VINCENT MUNSTER HAS

1278
00:56:37,720 --> 00:56:39,760
RISEN TO THE TASK HERE AND

1279
00:56:39,760 --> 00:56:41,640
STUDYING VIRAL EVOLUTION,

1280
00:56:41,640 --> 00:56:44,520
DIAGNOSTICS, THERAPEUTICS, AND

1281
00:56:44,520 --> 00:56:46,040
ENVIRONMENTAL STABILITY AS WELL

1282
00:56:46,040 --> 00:56:48,200
AS TRANSMISSION IN BOTH STUDIES

1283
00:56:48,200 --> 00:56:52,640
IN THE CONGO AS WELL AS IN

1284
00:56:52,640 --> 00:56:52,880
MONTANA.

1285
00:56:52,880 --> 00:56:54,600
MOVING TO SOME OF THE CHANGES IN

1286
00:56:54,600 --> 00:56:58,040
THE INTRAMURAL PROGRAM, WE'VE

1287
00:56:58,040 --> 00:56:59,840
HAD TWO NEW LABORATORY CHIEFS

1288
00:56:59,840 --> 00:57:02,800
SELECTED IN THE LAST YEAR AND

1289
00:57:02,800 --> 00:57:04,360
CAROLINA MURRAY WHO IS NOW THE

1290
00:57:04,360 --> 00:57:06,920
CHIEF OF THE LABORATORY OF

1291
00:57:06,920 --> 00:57:10,560
MALARIA VECTOR RESEARCH AND A

1292
00:57:10,560 --> 00:57:13,320
WORLD-RENOWNED INVESTIGATOR AND

1293
00:57:13,320 --> 00:57:15,080
SONIA BEST THE CHIEF OF THE LAB

1294
00:57:15,080 --> 00:57:16,640
TORE' OF PERSISTENT VIRAL

1295
00:57:16,640 --> 00:57:19,200
DISEASES NOW THE LABORATORY OF

1296
00:57:19,200 --> 00:57:20,680
NEWER LOGIC INFECTION AND

1297
00:57:20,680 --> 00:57:21,760
IMMUNITY.

1298
00:57:21,760 --> 00:57:23,320
SHE'S A VIROLOGIST AND

1299
00:57:23,320 --> 00:57:26,160
IMMUNOLOGIST WHO WILL MARY THOSE

1300
00:57:26,160 --> 00:57:27,920
THINGS TOGETHER AROUND -- MARRY

1301
00:57:27,920 --> 00:57:29,640
THESE THINGS AROUND THE

1302
00:57:29,640 --> 00:57:29,920
SYNDROMES.

1303
00:57:29,920 --> 00:57:31,600
WE'VE BEEN INCREASING OUR NUMBER

1304
00:57:31,600 --> 00:57:34,280
OF DEPUTY LAB CHIEFS IN

1305
00:57:34,280 --> 00:57:35,600
RECOGNITION THAT YOU KNOW, DEATH

1306
00:57:35,600 --> 00:57:38,040
TAXES AND ADMINISTRATIVE BURDENS

1307
00:57:38,040 --> 00:57:40,400
ARE ALL INEVITABLE PARTS OF LIFE

1308
00:57:40,400 --> 00:57:43,360
AND SO WE'VE BEEN GATHERING HELP

1309
00:57:43,360 --> 00:57:45,520
TO DO THIS AND IN THE LABORATORY

1310
00:57:45,520 --> 00:57:50,120
OF PARASITIC DISEASES, AMY

1311
00:57:50,120 --> 00:57:55,800
KLEEON AND ELODIE GHEDIN HAVE

1312
00:57:55,800 --> 00:57:56,680
JOINED THAT PROGRAM.

1313
00:57:56,680 --> 00:57:58,280
WE'VE BEEN ADDING TO OUR RANKS

1314
00:57:58,280 --> 00:58:02,400
AS WELL, THIS YEAR, WE HAVE A

1315
00:58:02,400 --> 00:58:04,640
TENURED INVESTIGATOR AND YOU SAW

1316
00:58:04,640 --> 00:58:05,720
ULA'S WORK ASK I'LL SHOW YOU

1317
00:58:05,720 --> 00:58:08,360
MORE OF THAT IN A MOMENT.

1318
00:58:08,360 --> 00:58:11,320
WE'VE GOT THREE-NEW TENURE TRACK

1319
00:58:11,320 --> 00:58:12,800
INVESTIGATORS COMING INTO THE

1320
00:58:12,800 --> 00:58:15,760
TOP TWO.

1321
00:58:15,760 --> 00:58:20,760
ERIC VAN DANG AND HAU  JIN ARE

1322
00:58:20,760 --> 00:58:24,000
JOINING AND ERIC WILL WORK ON

1323
00:58:24,000 --> 00:58:27,600
FUNGI AS PART OF THE MICRO BUY

1324
00:58:27,600 --> 00:58:32,080
HOME AND HAO JIN WILL WORK ON

1325
00:58:32,080 --> 00:58:33,920
NEURO LOGIC FUNCTION AND

1326
00:58:33,920 --> 00:58:36,320
IMMUNITY AND HOW THOSE TWO

1327
00:58:36,320 --> 00:58:41,160
THINGS INTERFACE AND TIJANA

1328
00:58:41,160 --> 00:58:43,320
IVANOVICH IS JOINING LOOKING AT

1329
00:58:43,320 --> 00:58:45,080
THE ULTRASTRUCTURE OF HOW

1330
00:58:45,080 --> 00:58:48,600
VIRUSES GET INTO AND LIVE WITHIN

1331
00:58:48,600 --> 00:58:48,880
CELLS.

1332
00:58:48,880 --> 00:58:50,720
JUST REMIND YOU, OUR TENURE

1333
00:58:50,720 --> 00:58:53,320
TRACK PROGRAM, WE HAVE SEVERAL

1334
00:58:53,320 --> 00:58:55,480
DIFFERENT ROADS THAT LEAD TO THE

1335
00:58:55,480 --> 00:58:56,920
SAME DESTINATION.

1336
00:58:56,920 --> 00:58:59,480
AND THERE BE CAN A TENURE TRACK

1337
00:58:59,480 --> 00:59:01,520
SEARCH SELECTED BY A LAB FROM AN

1338
00:59:01,520 --> 00:59:01,880
ADD.

1339
00:59:01,880 --> 00:59:05,600
THERE IS SOMETHING CALLED THE

1340
00:59:05,600 --> 00:59:07,520
EARLY STADTMAN PROCESS THAT ARE

1341
00:59:07,520 --> 00:59:09,040
OPEN APPLICATIONS BASIC SIGNS

1342
00:59:09,040 --> 00:59:11,200
AND THAT COME IN FROM ALL AROUND

1343
00:59:11,200 --> 00:59:11,840
THE COUND TREE AND AROUND THE

1344
00:59:11,840 --> 00:59:14,040
WORLD AND THE LASKER CLINICAL

1345
00:59:14,040 --> 00:59:16,080
PROGRAM WHICH IS AGAIN AN OPEN

1346
00:59:16,080 --> 00:59:18,160
PROCESS FOR CLINICAL APPLICANTS

1347
00:59:18,160 --> 00:59:19,640
AND THAT STAY HERE FOR FIVE

1348
00:59:19,640 --> 00:59:21,760
YEARS AND HAVE A CHANCE TO STAY

1349
00:59:21,760 --> 00:59:24,640
OR GO TO THE OUTSIDE WITH

1350
00:59:24,640 --> 00:59:26,640
SUPPORT AND THEN FOR ALL OF

1351
00:59:26,640 --> 00:59:27,800
THESE GROUPS, THERE'S WHAT IS

1352
00:59:27,800 --> 00:59:30,120
CALLED THE DISTINGUISHED SCHOLAR

1353
00:59:30,120 --> 00:59:32,720
PROGRAM WHICH IS FOR PEOPLE WITH

1354
00:59:32,720 --> 00:59:34,520
A DEMONSTRATED AND SIGNIFICANT

1355
00:59:34,520 --> 00:59:36,120
COMMITMENT TO DIVERSITY AND WE

1356
00:59:36,120 --> 00:59:38,400
ARE VERY PROUD TO HAVE EIGHT

1357
00:59:38,400 --> 00:59:42,080
DISTINGUISHED SCHOLARS IN THE

1358
00:59:42,080 --> 00:59:52,480
TIRIN TRA MURAL PROGRAM.

1359
00:59:58,400 --> 01:00:02,200
JOHN ZHANG LEFT TO FORM A

1360
01:00:02,200 --> 01:00:04,360
PROGRAM AT YALE AROUND BIG

1361
01:00:04,360 --> 01:00:06,040
OMICS-TYPE RESEARCH IN

1362
01:00:06,040 --> 01:00:06,760
IMMUNOLOGY AND YOU KNOW ABOUT

1363
01:00:06,760 --> 01:00:09,560
SOME OF OUR UPCOMING

1364
01:00:09,560 --> 01:00:09,920
RETIREMENTS.

1365
01:00:09,920 --> 01:00:13,320
TONY HAS MENTIONED HIS AND THE

1366
01:00:13,320 --> 01:00:21,160
HAR LA CALDWELL WILL STEP DOWN,M

1367
01:00:21,160 --> 01:00:24,120
LIDO WHO HAS BEEN A LEADER IN

1368
01:00:24,120 --> 01:00:28,800
BIOLOGY WILL BE RETIRING NEXT

1369
01:00:28,800 --> 01:00:29,200
YEAR.

1370
01:00:29,200 --> 01:00:31,080
ELLEN CHER WHO LED CURRENTLY

1371
01:00:31,080 --> 01:00:33,480
HELPS ONE OUR OX CAM PROGRAM

1372
01:00:33,480 --> 01:00:36,320
WILL BE STEPPING DOWN THIS YEAR.

1373
01:00:36,320 --> 01:00:39,160
ROCKY MOUNTAIN LABS, WE'VE HAD A

1374
01:00:39,160 --> 01:00:41,760
REAL TURNOVER WHICH IS WHY SOME

1375
01:00:41,760 --> 01:00:44,560
OF THE TENURE TRACKS LAST YEAR

1376
01:00:44,560 --> 01:00:51,000
ARE OUT THERE AND JOE HINABUSH,

1377
01:00:51,000 --> 01:00:59,240
BOB HEINESON, FRANK GHERADINI,

1378
01:00:59,240 --> 01:01:02,400
DANA SCOTT WHO LED THE ROCKY

1379
01:01:02,400 --> 01:01:04,280
MOUNTAIN VETERINARY BRANCH AND

1380
01:01:04,280 --> 01:01:06,160
PATTY ROSA WHO ALSO LED THE

1381
01:01:06,160 --> 01:01:07,840
LABORATORY OF BACK TERROLOGY FOR

1382
01:01:07,840 --> 01:01:11,200
MANY YEARS AND HAS BEEN A LIME

1383
01:01:11,200 --> 01:01:11,680
INVESTIGATORS.

1384
01:01:11,680 --> 01:01:15,120
ON THIS CAMPUS, WE HAVE TWO LAB

1385
01:01:15,120 --> 01:01:17,200
CLOSINGS THAT IS DIFFERENT THAN

1386
01:01:17,200 --> 01:01:17,640
RETIREMENT.

1387
01:01:17,640 --> 01:01:19,640
THESE PEOPLE WILL BE STAYING ON.

1388
01:01:19,640 --> 01:01:22,200
JOHN GALLON WILL BE CLOSING HIS

1389
01:01:22,200 --> 01:01:23,360
LABORATORY AFTER SEVERAL DECADES

1390
01:01:23,360 --> 01:01:26,080
AND I THINK FIVE DECADES OF

1391
01:01:26,080 --> 01:01:29,720
SUCCESSFUL CRITICAL WORK AND HE

1392
01:01:29,720 --> 01:01:32,680
WILL STILL ON FOR CLINICAL

1393
01:01:32,680 --> 01:01:33,840
RESEARCH AND THE CHIEF

1394
01:01:33,840 --> 01:01:35,720
SCIENTIFIC OFFICER OF THE

1395
01:01:35,720 --> 01:01:38,800
CLINICAL CENTER AND BOB MUNFORD

1396
01:01:38,800 --> 01:01:42,120
WHO HAS BEEN THE SENIOR

1397
01:01:42,120 --> 01:01:43,960
CLINICIAN IN THE LABORATORY OF

1398
01:01:43,960 --> 01:01:45,960
CLINICAL IMMUNOLOGY AND

1399
01:01:45,960 --> 01:01:47,520
MICROBIOLOGY WAS DEPUTY LAB

1400
01:01:47,520 --> 01:01:49,440
CHIEF FOR MANY YEARS AND HAS

1401
01:01:49,440 --> 01:01:52,160
BEEN OVERSEEING OUR SCIENTIFIC

1402
01:01:52,160 --> 01:01:55,600
REVIEWS WILL BE CLOSING DOWN HIS

1403
01:01:55,600 --> 01:01:56,240
SECTION BUT CONTINUING ON STAFF

1404
01:01:56,240 --> 01:01:58,080
FOR A WHILE.

1405
01:01:58,080 --> 01:02:01,640
THIS LEAVEs WITH SEVERAL

1406
01:02:01,640 --> 01:02:03,000
OPENINGS THAT WE'RE LOOKING TO

1407
01:02:03,000 --> 01:02:03,400
FILL.

1408
01:02:03,400 --> 01:02:05,080
WE REALLY WOULD APPRECIATE YOUR

1409
01:02:05,080 --> 01:02:07,440
HELP IN THIS.

1410
01:02:07,440 --> 01:02:10,920
THE ROCKY MOUNTAIN VET TRA NAIR

1411
01:02:10,920 --> 01:02:12,360
YAN BRANCH IS OPEN AND THE

1412
01:02:12,360 --> 01:02:14,280
LABORATORY OF ALLERGIC DISEASES

1413
01:02:14,280 --> 01:02:15,840
HAS TWO TENURE TRACK POSITIONS

1414
01:02:15,840 --> 01:02:19,160
IT'S LOOKING TO FILL AND THEN WE

1415
01:02:19,160 --> 01:02:21,000
ARE, AS YOU KNOW, LOOKING FOR

1416
01:02:21,000 --> 01:02:21,760
LABORATORY CHIEFS.

1417
01:02:21,760 --> 01:02:24,080
THE LABORATORY OF IMMUNO

1418
01:02:24,080 --> 01:02:25,840
REGULATIONS THAT IS TONY'S

1419
01:02:25,840 --> 01:02:27,000
LABORATORY, WILL BE LOOKING FOR

1420
01:02:27,000 --> 01:02:29,480
A NEW CHIEF IN THE NEXT YEAR AND

1421
01:02:29,480 --> 01:02:35,080
THE LABORATORY OF IMMUNOGENETICS

1422
01:02:35,080 --> 01:02:38,160
LED BY SUE PIERCE WHO WILL STEP

1423
01:02:38,160 --> 01:02:39,760
DOWN SOON, WILL LOOK FOR A

1424
01:02:39,760 --> 01:02:42,120
CANDIDATE INTERNALLY BECAUSE OF

1425
01:02:42,120 --> 01:02:45,000
SPACE CONSIDERATIONS.

1426
01:02:45,000 --> 01:02:46,600
JUST A COUPLE OF VERY QUICK

1427
01:02:46,600 --> 01:02:50,640
RESEARCH HIGHLIGHTS.

1428
01:02:50,640 --> 01:02:51,600
WE ARE STILL DOING A LOT OF

1429
01:02:51,600 --> 01:02:54,560
COVID WORK AS I KNOW MANY OF YOU

1430
01:02:54,560 --> 01:02:55,360
ARE AS WELL.

1431
01:02:55,360 --> 01:02:57,720
WE HAVE PUT TOGETHER A

1432
01:02:57,720 --> 01:02:59,000
MULTI-NATIONAL TRIAL TRYING TO

1433
01:02:59,000 --> 01:03:03,280
LOOK  AT A MULTI OMIC APPROACH O

1434
01:03:03,280 --> 01:03:06,240
CHILDREN LOOKING AT MISS C AND

1435
01:03:06,240 --> 01:03:08,600
AT PEDIATRIC ACUTE COVID AS WELL

1436
01:03:08,600 --> 01:03:10,240
AS HEALTHY CONTROLS AND I THINK

1437
01:03:10,240 --> 01:03:13,440
YOU CAN SEE HERE THE LARGE

1438
01:03:13,440 --> 01:03:16,080
NUMBER OF RED SPOTS ON THE LEFT

1439
01:03:16,080 --> 01:03:19,120
IN THE COHORT AND IN THE ACUTE

1440
01:03:19,120 --> 01:03:20,880
COHORT IN BLUE AND REALLY

1441
01:03:20,880 --> 01:03:25,360
IDENTIFYING THEM AS DISTINCT

1442
01:03:25,360 --> 01:03:26,920
DISEASES AND HE HAS BEEN

1443
01:03:26,920 --> 01:03:28,680
IDENTIFYING TARGETS.

1444
01:03:28,680 --> 01:03:33,160
KATIE BOSSOIO HAS BEEN IMMUNO

1445
01:03:33,160 --> 01:03:34,080
METABOLISM TO COVID.

1446
01:03:34,080 --> 01:03:35,600
LAST YEAR SHE WORKED ON THIS IN

1447
01:03:35,600 --> 01:03:38,240
A HUMAN COHORT FROM YALE AND

1448
01:03:38,240 --> 01:03:39,120
THIS YEAR SHE'S WORKING WHAT

1449
01:03:39,120 --> 01:03:43,920
DOES THE RECEPTORS FOR ADVANCES

1450
01:03:43,920 --> 01:03:45,240
GLY INDICATION OR RAGE HAS TO DO

1451
01:03:45,240 --> 01:03:47,320
WITH IT AND IF YOU BLOCK RAGE

1452
01:03:47,320 --> 01:03:49,160
YOU CAN INCREASE SURVIVAL IN A

1453
01:03:49,160 --> 01:03:51,080
MOUSE MODEL GIVING KATIE NEW

1454
01:03:51,080 --> 01:03:55,680
TARGETS TO GO AFTER IN TERMS OF

1455
01:03:55,680 --> 01:03:56,120
THERAPEUTICS.

1456
01:03:56,120 --> 01:03:57,560
FOLLOWING ALONG THE SAME SORT OF

1457
01:03:57,560 --> 01:03:59,840
HOW TO USE THE MOUSE MODEL,

1458
01:03:59,840 --> 01:04:02,120
SONIA BEST HAS PUT TOGETHER A

1459
01:04:02,120 --> 01:04:04,680
REALLY IMPORTANT STUDY WITH

1460
01:04:04,680 --> 01:04:07,760
NADDIA ROSENTHAL FROM JACK'S

1461
01:04:07,760 --> 01:04:09,840
LABS USING THE COLLABORATIVE

1462
01:04:09,840 --> 01:04:12,480
CROSS TO LOOK AT MOUSE GENETICS

1463
01:04:12,480 --> 01:04:13,680
AND HOW WE CAN USE THOSE.

1464
01:04:13,680 --> 01:04:15,440
I WANT TO POINT OUT HERE, ON THE

1465
01:04:15,440 --> 01:04:18,520
LEFT SIDE, YOU SEE IN THE

1466
01:04:18,520 --> 01:04:20,680
LEFT-TOP PANEL, MICE THAT DIE.

1467
01:04:20,680 --> 01:04:23,280
THESE ARE ACE 2 TRANSGENIC MICE

1468
01:04:23,280 --> 01:04:24,480
IN THE COLLABORATIVE CROSS.

1469
01:04:24,480 --> 01:04:25,920
THEY DIE WITH COVID.

1470
01:04:25,920 --> 01:04:28,720
OK, THEN THERE'S SOME MICE THAT

1471
01:04:28,720 --> 01:04:31,000
ARE RESISTANT THAT TELL US MOUSE

1472
01:04:31,000 --> 01:04:35,040
GENES WE CAN GO AND IDENTIFY.

1473
01:04:35,040 --> 01:04:36,760
IF YOU GO INFORM THE RIGHT SIDE,

1474
01:04:36,760 --> 01:04:38,280
IT'S LESS EXPECT AND MORE

1475
01:04:38,280 --> 01:04:38,600
INTERESTING.

1476
01:04:38,600 --> 01:04:40,560
WHAT YOU SEE ON THE TOP, IS THAT

1477
01:04:40,560 --> 01:04:43,520
HERE IS A STRAIN OF MICE IN

1478
01:04:43,520 --> 01:04:45,440
WHICH THE MALES ARE DRAMATICALLY

1479
01:04:45,440 --> 01:04:48,520
MORE SUSCEPTIBLE TO COVID

1480
01:04:48,520 --> 01:04:50,640
INFECTION AND NOT TOO DISSIMILAR

1481
01:04:50,640 --> 01:04:52,720
FROM WHAT IS SEEN IN HUMANS AND

1482
01:04:52,720 --> 01:04:56,200
ON THE BOTTOM, YOU SEE STRAINS

1483
01:04:56,200 --> 01:04:59,760
ONLY THE FEMALE CARRY THE HIGH

1484
01:04:59,760 --> 01:05:00,240
SUSCEPTIBLE.

1485
01:05:00,240 --> 01:05:02,720
IT'S FASCINATING TO DISSECT THE

1486
01:05:02,720 --> 01:05:03,720
GENETICS IN THE MOUSE THAT WE

1487
01:05:03,720 --> 01:05:07,560
CAN GO BACK TO THE HUMAN TO

1488
01:05:07,560 --> 01:05:09,200
INTERROGATE.

1489
01:05:09,200 --> 01:05:12,040
FINALLY, ULA BUCKHOLD WORKS ON

1490
01:05:12,040 --> 01:05:14,680
TRYING TO IDENTIFY VACCINES THAT

1491
01:05:14,680 --> 01:05:16,600
ARE GOOD AGAINST COVID.

1492
01:05:16,600 --> 01:05:19,440
SHE'S VERY INTERESTING IN RSV

1493
01:05:19,440 --> 01:05:20,960
AND OTHER INFECTIONS AS WELL.

1494
01:05:20,960 --> 01:05:22,640
IN THIS PARTICULAR PAPER, STILL

1495
01:05:22,640 --> 01:05:24,680
IN THE PRE PRINT, WHAT YOU SEE

1496
01:05:24,680 --> 01:05:28,080
IS IS SHE'S USING THE BOVINE

1497
01:05:28,080 --> 01:05:31,520
HUMAN PARA 3 TO MAKE A SPIKE

1498
01:05:31,520 --> 01:05:33,560
EXPRESSING VIRUS THAT IS HIGHLY

1499
01:05:33,560 --> 01:05:35,120
STABILIZED AND WHAT YOU CAN SEE

1500
01:05:35,120 --> 01:05:37,280
HERE, IF YOU LOOK AT THE BOTTOM

1501
01:05:37,280 --> 01:05:39,520
PANEL, IN LUNG TISSUE, YOU CAN

1502
01:05:39,520 --> 01:05:43,040
REALLY PREVENT THE PROLIFERATION

1503
01:05:43,040 --> 01:05:49,480
OF SARS-CoV-2 AFTER A VIRUS

1504
01:05:49,480 --> 01:05:51,640
CHALLENGE IN MACAQUES.

1505
01:05:51,640 --> 01:05:53,400
SO HOPE THAT THIS MUCOSAL

1506
01:05:53,400 --> 01:05:55,640
VACCINE COULD BE USEFUL.

1507
01:05:55,640 --> 01:05:57,040
NOW, YOU KNOW, HAS THERE NOT

1508
01:05:57,040 --> 01:05:58,600
MORE THAN COVID?

1509
01:05:58,600 --> 01:05:59,280
OF COURSE.

1510
01:05:59,280 --> 01:06:00,480
AND THERE WILL CONTINUE TO BE

1511
01:06:00,480 --> 01:06:02,880
MORE THAN COVID.

1512
01:06:02,880 --> 01:06:03,640
WE HAVE OTHER PANDEMIC THREATS

1513
01:06:03,640 --> 01:06:09,560
TO WORRY ABOUT, HINES FELDMAN

1514
01:06:09,560 --> 01:06:11,760
WORKS ON FEVER.

1515
01:06:11,760 --> 01:06:15,360
CAN YOU SEE THIS VIRUS THAT THIS

1516
01:06:15,360 --> 01:06:19,760
VACCINES THAT IS PROFOUNDLY

1517
01:06:19,760 --> 01:06:22,720
PROSPECTIVE AGAINST CCHF AND

1518
01:06:22,720 --> 01:06:26,160
HEINZ HAS BEEN TAKING THIS

1519
01:06:26,160 --> 01:06:26,400
FORWARD.

1520
01:06:26,400 --> 01:06:29,120
WE STILL HAVE MANY DIFFERENT

1521
01:06:29,120 --> 01:06:32,800
CONTROLS TO UNDERSTAND HOW

1522
01:06:32,800 --> 01:06:33,960
IMMUNE FUNCTION AND DYSFUNCTION

1523
01:06:33,960 --> 01:06:34,160
WORK.

1524
01:06:34,160 --> 01:06:36,880
HERE IN THIS REALLY ELEGANT

1525
01:06:36,880 --> 01:06:40,400
TRANS INSTITUTE COLLABORATION

1526
01:06:40,400 --> 01:06:44,680
BETWEEN YASMIN AND JULIE AND LED

1527
01:06:44,680 --> 01:06:49,160
LOOKING HOW IS IT THAT

1528
01:06:49,160 --> 01:06:49,840
ANTIBIOTICS, PRE DISPOSE TO

1529
01:06:49,840 --> 01:06:50,800
FUNCTIONAL INFECTION.

1530
01:06:50,800 --> 01:06:52,680
WE DON'T TYPICALLY THINK ABOUT

1531
01:06:52,680 --> 01:06:53,920
BACTERIA BEING THE CAUSE OF

1532
01:06:53,920 --> 01:06:55,400
FUNGAL DISEASE BUT AS YOU SEE IN

1533
01:06:55,400 --> 01:06:57,200
THIS SCHEMATIC ON THE LEFT, IT'S

1534
01:06:57,200 --> 01:06:59,640
THE REDUCTION IN CERTAIN

1535
01:06:59,640 --> 01:07:02,040
BACTERIA AND THE GROUND POSITIVE

1536
01:07:02,040 --> 01:07:05,320
CATEGORY THAT DIMINISH THE TH-17

1537
01:07:05,320 --> 01:07:10,360
ACTIVATION THAT ALLOW FOR FUNGAL

1538
01:07:10,360 --> 01:07:12,040
PROLIFERATION AND CANADA DEEMIA

1539
01:07:12,040 --> 01:07:15,040
AND PUTTING THESE MECHANISMS

1540
01:07:15,040 --> 01:07:16,520
INTO CONTEXT IS WHAT WILL GIVE

1541
01:07:16,520 --> 01:07:18,400
US REAL INSIGHTS TO GO FORWARD

1542
01:07:18,400 --> 01:07:19,720
AND IDENTIFY SOME OF THE WAYS

1543
01:07:19,720 --> 01:07:21,600
THAT WE TREAT OUR INTENSIVE CARE

1544
01:07:21,600 --> 01:07:23,760
PATIENTS AND SO ON.

1545
01:07:23,760 --> 01:07:27,240
AND THEN STAYING WITH THE BOWEL

1546
01:07:27,240 --> 01:07:30,280
AS CRITICAL SITE OF ACTIVITY,

1547
01:07:30,280 --> 01:07:31,800
MIKE LEARNARD OWE AND CO-WORKERS

1548
01:07:31,800 --> 01:07:36,240
TOOK A HUMAN MUTATION THAT WAS

1549
01:07:36,240 --> 01:07:39,480
RECOGNIZED IN A GENE INVOLVED IN

1550
01:07:39,480 --> 01:07:40,880
MUCUS PRODUCTION TO RECOGNIZE

1551
01:07:40,880 --> 01:07:45,360
THE CRITICAL ROLE FOR MUCUS

1552
01:07:45,360 --> 01:07:47,640
SIGHALLATION IN MANAGING

1553
01:07:47,640 --> 01:07:56,440
INDESTINATION HOST COMME COMMENE

1554
01:07:56,440 --> 01:07:56,840
HOMEOSTASIS.

1555
01:07:56,840 --> 01:07:58,720
IT HAS GIVEN US NEW IN SIGHT

1556
01:07:58,720 --> 01:08:00,600
INTO HOW THE BOWEL FUNCTIONS AND

1557
01:08:00,600 --> 01:08:01,680
HOW THE BOWEL PROTECTS ITSELF

1558
01:08:01,680 --> 01:08:05,920
FROM INVASION.

1559
01:08:05,920 --> 01:08:07,360
LASTLY, AS I CAME INTO THIS

1560
01:08:07,360 --> 01:08:08,880
POSITION SEVERAL YEARS AGO, WE

1561
01:08:08,880 --> 01:08:12,800
TALKED ABOUT A NEW APPROACH TO

1562
01:08:12,800 --> 01:08:15,240
DOING HUMAN EX OWN SEQUENCE AND

1563
01:08:15,240 --> 01:08:17,960
NOW HUMAN GENOME SEQUENCING.

1564
01:08:17,960 --> 01:08:19,480
I WANT TO SHARE THE RESULTS OF

1565
01:08:19,480 --> 01:08:20,920
THE FIRST 1,000 INDIVIDUALS SO

1566
01:08:20,920 --> 01:08:22,920
OUR APPROACH HERE IS THAT EVERY

1567
01:08:22,920 --> 01:08:25,000
PATIENT WHO COMES INTO THE

1568
01:08:25,000 --> 01:08:26,960
NIAID, WHETHER THEY'RE NORMAL

1569
01:08:26,960 --> 01:08:29,760
VOLUNTEER OR HIV INFECTED,

1570
01:08:29,760 --> 01:08:30,560
IMMUNODEFICIENCY IS OFFERED THE

1571
01:08:30,560 --> 01:08:34,200
CHANCE TO HAVE A WHOLE GENOME

1572
01:08:34,200 --> 01:08:36,800
SEQUENCE DONE AND THE FIRST

1573
01:08:36,800 --> 01:08:38,440
1,000 PATIENTS THAT WERE

1574
01:08:38,440 --> 01:08:41,960
SEQUENCES ARE SHOWN HERE.

1575
01:08:41,960 --> 01:08:43,240
IT'S TOO SMALL TO READ WHAT THE

1576
01:08:43,240 --> 01:08:45,080
GENES ARE AND IT'S VERY SKEWED

1577
01:08:45,080 --> 01:08:46,320
TOWARDS THE DISEASES THAT WE

1578
01:08:46,320 --> 01:08:48,760
STUDY A LOT OF.

1579
01:08:48,760 --> 01:08:50,480
IF WE BREAK IT DOWN WHAT'S DID

1580
01:08:50,480 --> 01:08:52,520
WE FIND IN LOOKING AT THE FIRST

1581
01:08:52,520 --> 01:08:52,880
1,000.

1582
01:08:52,880 --> 01:08:57,040
WE FOUND MOLECULAR DIAGNOSIS IN

1583
01:08:57,040 --> 01:08:57,520
33%.

1584
01:08:57,520 --> 01:08:59,560
17 OF THOSE PEOPLE HAD COPY

1585
01:08:59,560 --> 01:09:02,160
NUMBER VARIANTS, KIND OF STUFF

1586
01:09:02,160 --> 01:09:04,840
YOU DON'T PICK UP ON WHOLE EX

1587
01:09:04,840 --> 01:09:07,600
OWN SEQUENCING AND 32 OF THOSE

1588
01:09:07,600 --> 01:09:09,200
PEOPLE HAD SECONDARY FINDINGS

1589
01:09:09,200 --> 01:09:10,680
THAT'S THE KIND OF GENETIC

1590
01:09:10,680 --> 01:09:11,600
PROBLEMS THAT THE AMERICAN

1591
01:09:11,600 --> 01:09:13,840
COLLEGE OF MEDICAL GENETICS SAYS

1592
01:09:13,840 --> 01:09:15,280
YOU NEED TO TELL PEOPLE ABOUT

1593
01:09:15,280 --> 01:09:16,840
THIS WHETHER IT'S BRACK A 2 OR

1594
01:09:16,840 --> 01:09:20,080
SOMETHING LIKE THAT.

1595
01:09:20,080 --> 01:09:21,840
AND THEN 31 PEOPLE HAD MULTIPLE

1596
01:09:21,840 --> 01:09:24,200
MOLECULAR DIAGNOSIS.

1597
01:09:24,200 --> 01:09:27,160
IF YOU HAVE ONE MENDILIAN

1598
01:09:27,160 --> 01:09:28,800
MUTATION, WHAT'S THE LIKELIHOOD

1599
01:09:28,800 --> 01:09:30,120
YOU HAVE A SECOND ONE AND THE

1600
01:09:30,120 --> 01:09:31,840
RATE FROM THAT RANGES FROM FIVE

1601
01:09:31,840 --> 01:09:32,440
TO 10%.

1602
01:09:32,440 --> 01:09:35,040
THINK ABOUT IT, JUST BECAUSE YOU

1603
01:09:35,040 --> 01:09:36,240
GOT ONE PROBLEM, DOESN'T MEAN

1604
01:09:36,240 --> 01:09:40,000
YOU DON'T HAVE TWO AND THEN IN

1605
01:09:40,000 --> 01:09:42,200
AR PARADIGM FOR WHERE WE'RE

1606
01:09:42,200 --> 01:09:44,560
GOING, REANAL SIGHS IDENTIFIED

1607
01:09:44,560 --> 01:09:48,000
22 MORE DIAGNOSIS AND IN NINE OF

1608
01:09:48,000 --> 01:09:49,480
THOSE 22, THEY WERE NOVEL

1609
01:09:49,480 --> 01:09:52,080
DISEASE GENE ASSOCIATIONS.

1610
01:09:52,080 --> 01:09:55,600
SO, THIS IS REALLY WHERE THE

1611
01:09:55,600 --> 01:09:57,480
FIELD IS HEADED AND I THINK

1612
01:09:57,480 --> 01:10:00,520
WHERE WE'RE TAKING A GOOD ROLE

1613
01:10:00,520 --> 01:10:01,120
HERE.

1614
01:10:01,120 --> 01:10:02,680
SO, COMING TO THE END HERE, WHAT

1615
01:10:02,680 --> 01:10:04,360
ARE OUR FUTURE DIRECTION THIS IS

1616
01:10:04,360 --> 01:10:05,240
WE'RE OBVIOUSLY STILL WORKING

1617
01:10:05,240 --> 01:10:07,000
HARD TO RECRUIT TALENTED AND

1618
01:10:07,000 --> 01:10:12,800
DIVERSE INVESTIGATORS AND HE

1619
01:10:12,800 --> 01:10:14,960
WANT TO FOSTER THESE

1620
01:10:14,960 --> 01:10:15,800
BENCH-TO-BET SIDE APPROACH AND

1621
01:10:15,800 --> 01:10:17,640
MAKE SURE THE CLINICAL CENTER

1622
01:10:17,640 --> 01:10:19,200
RESOURCES ARE AVAILABLE TO ALL

1623
01:10:19,200 --> 01:10:20,720
LABS, WHETHER BASIC OR CLINICAL.

1624
01:10:20,720 --> 01:10:22,040
THAT IS WHERE WE CAN BRING THIS

1625
01:10:22,040 --> 01:10:22,720
ALL TOGETHER.

1626
01:10:22,720 --> 01:10:25,280
WE WANT TO PROMOTE THIS STUDY OF

1627
01:10:25,280 --> 01:10:27,560
PATHO PHYSIOLOGY, INNOVATIVE

1628
01:10:27,560 --> 01:10:28,960
STRATEGIES, VACCINES TARGETS,

1629
01:10:28,960 --> 01:10:30,480
DIAGNOSTICS AND THERAPEUTICS AND

1630
01:10:30,480 --> 01:10:33,120
ENCOURAGE OUR EXTRAMURAL AND

1631
01:10:33,120 --> 01:10:36,080
INTERNATIONAL COLLABORATIONS.

1632
01:10:36,080 --> 01:10:37,320
SO, NOW I'VE FINISHED THAT PART

1633
01:10:37,320 --> 01:10:39,040
AND GIVE ONE LAST THING I NEED

1634
01:10:39,040 --> 01:10:40,320
TO ASK FOR YOUR HELP WITH AND

1635
01:10:40,320 --> 01:10:42,920
THIS IS CALLED A CONCEPT

1636
01:10:42,920 --> 01:10:43,240
CLEARANCE.

1637
01:10:43,240 --> 01:10:44,320
SOMETIMES WE DO THIS IN THE

1638
01:10:44,320 --> 01:10:45,480
SMALLER GROUPS AND I'M GOING TO

1639
01:10:45,480 --> 01:10:47,800
TAKE ADVANTAGE OF HAVING YOU

1640
01:10:47,800 --> 01:10:48,520
ASSEMBLED HERE.

1641
01:10:48,520 --> 01:10:51,600
WE NEED YOUR ADVICE ON WHETHER

1642
01:10:51,600 --> 01:10:53,600
WE CAN GO FORWARD WITH

1643
01:10:53,600 --> 01:10:54,440
IMPLEMENTING THIS APPROACH.

1644
01:10:54,440 --> 01:10:56,880
SO THE CONCEPT CLEARANCE IS FOR

1645
01:10:56,880 --> 01:10:58,320
SCIENTIFIC AND TECHNICAL STAFF

1646
01:10:58,320 --> 01:11:01,080
AND SERVICES TO SUPPORT

1647
01:11:01,080 --> 01:11:03,440
COLLABORATION WITH THE UGANDA

1648
01:11:03,440 --> 01:11:05,200
VIRUS RESEARCH INSTITUTE ON

1649
01:11:05,200 --> 01:11:07,840
EMERGING INFECTIOUS DISEASES.

1650
01:11:07,840 --> 01:11:09,960
SO, PRIOR TO ANY MAJOR NIH

1651
01:11:09,960 --> 01:11:11,960
CONTRACT SOLICITATIONS, THE

1652
01:11:11,960 --> 01:11:13,240
SCIENTIFIC CONCEPT MUST BE

1653
01:11:13,240 --> 01:11:15,280
APPROVED BY A FEDERAL ADVISORY

1654
01:11:15,280 --> 01:11:17,640
COMMITTEE SUCH AS A BSC AND THE

1655
01:11:17,640 --> 01:11:19,400
INSTITUTE SENIOR LEADERSHIP.

1656
01:11:19,400 --> 01:11:20,840
AND THE CONSIDERATIONS INCLUDE

1657
01:11:20,840 --> 01:11:22,800
HERE THE PURPOSE, THE SCOPE, AND

1658
01:11:22,800 --> 01:11:25,160
THE OBJECTIVES OF THE CONTRACT.

1659
01:11:25,160 --> 01:11:29,160
SO, IN BROAD OUTLINES, WE WANT

1660
01:11:29,160 --> 01:11:31,280
TO OBTAIN PERSONNEL AND

1661
01:11:31,280 --> 01:11:33,080
SCIENTIFIC SERVICE TO SUPPORT

1662
01:11:33,080 --> 01:11:34,520
LABORATORY AND FIELD-BASED

1663
01:11:34,520 --> 01:11:37,720
RESEARCH AT THE UGANDA VIRUS

1664
01:11:37,720 --> 01:11:40,560
RESEARCH INSTITUTE IN UGANDA AND

1665
01:11:40,560 --> 01:11:41,040
FIELD COLLECTION SITES

1666
01:11:41,040 --> 01:11:42,120
THROUGHOUT UGANDA.

1667
01:11:42,120 --> 01:11:43,920
THIS IS IN ORDER TO SUPPORT ON

1668
01:11:43,920 --> 01:11:45,320
GOING RESEARCH COLLABORATIONS

1669
01:11:45,320 --> 01:11:50,520
BETWEEN THE LABORATORY OF

1670
01:11:50,520 --> 01:11:51,960
VIROLOGY HINES FELDMAN AND

1671
01:11:51,960 --> 01:11:52,600
VINCENT MUNSTER IN PARTICULAR

1672
01:11:52,600 --> 01:11:54,560
AND THE UVRI ON EMERGING

1673
01:11:54,560 --> 01:11:55,560
INFECTIOUS DISEASES.

1674
01:11:55,560 --> 01:11:56,680
OTHER LABORATORIES MAY

1675
01:11:56,680 --> 01:11:58,800
PARTICIPATE IN THE FUTURE.

1676
01:11:58,800 --> 01:12:00,240
SOME OF YOU MAY KNOW THE

1677
01:12:00,240 --> 01:12:02,240
LABORATORY OF IMMUNE REGULATION

1678
01:12:02,240 --> 01:12:04,960
HAS A PROGRAM THERE WITH TOM

1679
01:12:04,960 --> 01:12:06,680
QUINN ALREADY IN UGANDA.

1680
01:12:06,680 --> 01:12:08,280
AND THE OBJECTIVE HERE IS TO

1681
01:12:08,280 --> 01:12:09,880
SUPPORT THE UGANDA RESEARCHERS

1682
01:12:09,880 --> 01:12:13,120
AND RESEARCH SUPPORT STAFF AND

1683
01:12:13,120 --> 01:12:15,200
SERVICES WITH RESEARCH SUPPORT

1684
01:12:15,200 --> 01:12:18,040
STAFF AND SERVICES REQUIRED TO

1685
01:12:18,040 --> 01:12:19,720
FACILITATE APPROPRIATELY

1686
01:12:19,720 --> 01:12:21,960
REVIEWED AND APPROVED LABORATORY

1687
01:12:21,960 --> 01:12:23,480
AND FIELD BASED STUDIES ON

1688
01:12:23,480 --> 01:12:25,840
EMERGING INFECTIOUS DISEASES IN

1689
01:12:25,840 --> 01:12:27,760
UGANDA SO WE'RE ASKING FOR YOUR

1690
01:12:27,760 --> 01:12:29,800
A APPROVAL AND THIS WILL BE

1691
01:12:29,800 --> 01:12:31,800
DETERMINED AT THE DMID

1692
01:12:31,800 --> 01:12:33,640
DISCUSSION LATER ON TODAY AND

1693
01:12:33,640 --> 01:12:35,200
WE'RE ASKING FOR YOUR APPROVAL

1694
01:12:35,200 --> 01:12:37,080
OF THE CONCEPT THAT WE WOULD BE

1695
01:12:37,080 --> 01:12:39,600
ABLE TO GO FORWARD WITH THIS.

1696
01:12:39,600 --> 01:12:40,680
I'LL STOP THERE AND SAY THANK

1697
01:12:40,680 --> 01:12:42,200
YOU, VERY MUCH AND I WILL BE

1698
01:12:42,200 --> 01:12:48,200
HAPPY TO TAKE ANY QUESTIONS.

1699
01:12:48,200 --> 01:12:49,520
>> ARE THERE ANY QUESTIONS
OF

1700
01:12:49,520 --> 01:12:57,320
STEVE ON HIS PRESENTATION?

1701
01:12:57,320 --> 01:12:59,520
ALL RIGHT.

1702
01:12:59,520 --> 01:13:01,160
SEEING NONE, WHAT WE'LL DO RIGHT

1703
01:13:01,160 --> 01:13:02,800
NOW, THANK YOU SO MUCH, STEVE.

1704
01:13:02,800 --> 01:13:03,320
I APPRECIATE IT.

1705
01:13:03,320 --> 01:13:05,440
>> THANK YOU, TONY.

1706
01:13:05,440 --> 01:13:06,120
>> Dr. Anthony S. Fauci:
SO, WE

1707
01:13:06,120 --> 01:13:07,680
WANT TO TAKE A COUPLE OF MINUTE

1708
01:13:07,680 --> 01:13:08,520
BREAK.

1709
01:13:08,520 --> 01:13:13,280
MATTHEW, SINCE WE'RE DOING THIS

1710
01:13:13,280 --> 01:13:15,680
VIRTUALLY, HOW LONG DO WE -- WE

1711
01:13:15,680 --> 01:13:18,280
JUST NEED PEOPLE WHO ARE NON

1712
01:13:18,280 --> 01:13:20,760
HARE-GOVERNMENT, WE WOULD ASK

1713
01:13:20,760 --> 01:13:21,920
THEM TO LEAVE THE ROOM SO WE CAN

1714
01:13:21,920 --> 00:00:00,000
MOVE INTO THE CLOSED SESSION